{
  "doc_id": "1_aspen_fluids_and_electrolytes__5dab52",
  "original_filename": "1. ASPEN Fluids and electrolytes.pdf",
  "md_path": "data/parsed/1. ASPEN Fluids and electrolytes/1. ASPEN Fluids and electrolytes.md",
  "rmd_path": "data/parsed/1. ASPEN Fluids and electrolytes/1. ASPEN Fluids and electrolytes.rmd",
  "blocks": [
    {
      "type": "image",
      "section": "",
      "line": 0,
      "content": "![img-0.jpeg](images/7a8dca012bcc4a8f.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course Fluids and Electrolytes",
      "line": 2
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course Fluids and Electrolytes",
      "line": 4,
      "preview": "**Wednesday, July 30, 2025**"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course Fluids and Electrolytes",
      "line": 5,
      "preview": "3:00 pm \u2013 4:30 pm ET"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "SESSION HANDOUT",
      "line": 7
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 9,
      "preview": "|   | Page  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 10,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 11,
      "preview": "|  Accreditation Information | 2  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 12,
      "preview": "|  How to Claim CE Credit and Access CE Transcript | 3-6  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 13,
      "preview": "|  How to Access Recording and Handout | 7  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 14,
      "preview": "|  Session Slides | 8-48  |"
    },
    {
      "type": "table",
      "section": "SESSION HANDOUT",
      "line": 15,
      "preview": "|  Self-Assessment Q&A | 49-51  |"
    },
    {
      "type": "text",
      "section": "SESSION HANDOUT",
      "line": 17,
      "preview": "--- page 1 ---"
    },
    {
      "type": "text",
      "section": "SESSION HANDOUT",
      "line": 19,
      "preview": "Nutrition Support Fundamentals Course: Fluids and Electrolytes July 30, 2025, 3:00 pm - 4:30 pm East"
    },
    {
      "type": "text",
      "section": "SESSION HANDOUT",
      "line": 21,
      "preview": "Course Goal and Target Audience: The American Society for Enteral and Parenteral Nutrition (ASPEN) p"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Course Objectives:",
      "line": 23
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Fluids and Electrolytes",
      "line": 25
    },
    {
      "type": "text",
      "section": "Fluids and Electrolytes",
      "line": 27,
      "preview": "1. Assess fluid and electrolyte needs of a patient"
    },
    {
      "type": "text",
      "section": "Fluids and Electrolytes",
      "line": 28,
      "preview": "2. Develop a therapeutic plan for fluid and electrolyte requirements"
    },
    {
      "type": "text",
      "section": "Fluids and Electrolytes",
      "line": 29,
      "preview": "3. Prevent and manage complications of fluid and electrolyte abnormalities"
    },
    {
      "type": "text",
      "section": "Fluids and Electrolytes",
      "line": 31,
      "preview": "Successful Completion: CE credit must be claimed by August 30, 2025. To obtain credit for the webina"
    },
    {
      "type": "text",
      "section": "Fluids and Electrolytes",
      "line": 33,
      "preview": "Pharmacists and physicians, please note that ASPEN will upload earned CE credit into the appropriate"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Policies and Information:",
      "line": 35
    },
    {
      "type": "text",
      "section": "Policies and Information:",
      "line": 37,
      "preview": "Non-Commercialism. ASPEN subscribes to the Standards for Integrity and Independence in Accredited Co"
    },
    {
      "type": "text",
      "section": "Policies and Information:",
      "line": 39,
      "preview": "Privacy and Confidentiality. ASPEN respects the privacy of its members and customers. Companies that"
    },
    {
      "type": "text",
      "section": "Policies and Information:",
      "line": 41,
      "preview": "Grievances. Grievances must be submitted in writing to Senior Director, Education and Research at AS"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Commercial Support and Sponsorship:",
      "line": 43
    },
    {
      "type": "text",
      "section": "Commercial Support and Sponsorship:",
      "line": 45,
      "preview": "Commercial Support: None"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Accreditation Statement",
      "line": 47
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 49,
      "preview": "In support of improving patient care, The American Society for Parenteral and Enteral Nutrition (ASP"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 51,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 53,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 55,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 57,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 59,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 60,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 61,
      "preview": "|  Dietetic Registration | Completion of the 60,000 profession specific or PCE activity awards CPE t"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 62,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 63,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 64,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 65,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 66,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 68,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 70,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 72,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 74,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 76,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 77,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 78,
      "preview": "|  Dietetic Registration | Completion of the 60,000 profession specific or PCE activity awards CPE t"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 79,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 80,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 81,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 82,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 83,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 85,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 87,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 89,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 91,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 93,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 94,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 95,
      "preview": "|  Dietetic Registration | Completion of the 60,000 profession specific or PCE activity awards CPE t"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 96,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 97,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 98,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 99,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 100,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 102,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 104,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 106,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 108,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 110,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 111,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 112,
      "preview": "|  Dietetic Registration | Completion of the 60,000 profession specific or PCE activity awards CPE t"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 113,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 114,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 115,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 116,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 117,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 119,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 121,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 123,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 125,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 127,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 128,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 129,
      "preview": "|  Dietetic Registration | Completion of the 60,000 profession specific or PCE activity awards CPE t"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 130,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 131,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 132,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 133,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 134,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 136,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 138,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 140,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 142,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 144,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 145,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 146,
      "preview": "|  Dietetic Registration | Completion of the 60,000 profession specific or PCE activity awards CPE t"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 147,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 148,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 149,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 150,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 151,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 153,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 155,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 contact hours/0.15 CEUs. ACPE UAN: "
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 157,
      "preview": "Nurses: ASPEN designates this activity for a maximum of 1.5 nursing contact hours."
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 159,
      "preview": "Dietitians: ASPEN designates this activity for a maximum of 1.5 CPEUs."
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 161,
      "preview": "|  Commission on |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 162,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 163,
      "preview": "|  Dietetic Registration | Completion of the 60,000 profession specific or PCE activity awards CPE t"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 164,
      "preview": "|  Academic Accreditation and |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 165,
      "preview": "|  Education (ACCME), Accreditation Council for |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 166,
      "preview": "|  Pharmacy Education (ACPE), and the American Nurses Credentialing |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 167,
      "preview": "|  Center (ANCC), to provide continuing education for the healthcare |   |"
    },
    {
      "type": "table",
      "section": "Accreditation Statement",
      "line": 168,
      "preview": "|  team. |   |"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 170,
      "preview": "ASPEN designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T M}$. Phy"
    },
    {
      "type": "text",
      "section": "Accreditation Statement",
      "line": 172,
      "preview": "Pharmacists: ASPEN designates this activity for a maximum of 1.5 AMA PRA Category 1 Credits ${ }^{T "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2000 and 2001: an equal opportunity to enter into the program",
      "line": 174
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2001: an equal opportunity to enter into the program",
      "line": 176
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2002: an equal opportunity to enter into the program",
      "line": 178
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2003: an equal opportunity to enter into the program",
      "line": 180
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2004: an equal opportunity to enter into the program",
      "line": 182
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2005: an equal opportunity to enter into the program",
      "line": 184
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2006: an equal opportunity to enter into the program",
      "line": 186
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2007: an equal opportunity to enter into the program",
      "line": 188
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2008: an equal opportunity to enter into the program",
      "line": 190
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2009: an equal opportunity to enter into the program",
      "line": 192
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2010: an equal opportunity to enter into the program",
      "line": 194
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2011: an equal opportunity to enter into the program",
      "line": 196
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2012: an equal opportunity to enter into the program",
      "line": 198
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2013: an equal opportunity to enter into the program",
      "line": 200
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2014: an equal opportunity to enter into the program",
      "line": 202
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2015: an equal opportunity to enter into the program",
      "line": 204
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2016: an equal opportunity to enter into the program",
      "line": 206
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2017: an equal opportunity to enter into the program",
      "line": 208
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2018: an equal opportunity to enter into the program",
      "line": 210
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2019: an equal opportunity to enter into the program",
      "line": 212
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2020: an equal opportunity to enter into the program",
      "line": 214
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2021: an equal opportunity to enter into the program",
      "line": 216
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2022: an equal opportunity to enter into the program",
      "line": 218
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2023: an equal opportunity to enter into the program",
      "line": 220
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2024: an equal opportunity to enter into the program",
      "line": 222
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2025: an equal opportunity to enter into the program",
      "line": 224
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2026: an equal opportunity to enter into the program",
      "line": 226
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2027: an equal opportunity to enter into the program",
      "line": 228
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2028: an equal opportunity to enter into the program",
      "line": 230
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2029: an equal opportunity to enter into the program",
      "line": 232
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2030: an equal opportunity to enter into the program",
      "line": 234
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2031: an equal opportunity to enter into the program",
      "line": 236
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2032: an equal opportunity to enter into the program",
      "line": 238
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2033: an equal opportunity to enter into the program",
      "line": 240
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2034: an equal opportunity to enter into the program",
      "line": 242
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2035: an equal opportunity to enter into the program",
      "line": 244
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2036: an equal opportunity to enter into the program",
      "line": 246
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2037: an equal opportunity to enter into the program",
      "line": 248
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2038: an equal opportunity to enter into the program",
      "line": 250
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2039: an equal opportunity to enter into the program",
      "line": 252
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2040: an equal opportunity to enter into the program",
      "line": 254
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2041: an equal opportunity to enter into the program",
      "line": 256
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2042: an equal opportunity to enter into the program",
      "line": 258
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2043: an equal opportunity to enter into the program",
      "line": 260
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2044: an equal opportunity to enter into the program",
      "line": 262
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2045: an equal opportunity to enter into the program",
      "line": 264
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2046: an equal opportunity to enter into the program",
      "line": 266
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2047: an equal opportunity to enter into the program",
      "line": 268
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2048: an equal opportunity to enter into the program",
      "line": 270
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2049: an equal opportunity to enter into the program",
      "line": 272
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2050: an equal opportunity to enter into the program",
      "line": 274
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2051: an equal opportunity to enter into the program",
      "line": 276
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2052: an equal opportunity to enter into the program",
      "line": 278
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2053: an equal opportunity to enter into the program",
      "line": 280
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2054: an equal opportunity to enter into the program",
      "line": 282
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2055: an equal opportunity to enter into the program",
      "line": 284
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2056: an equal opportunity to enter into the program",
      "line": 286
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2057: an equal opportunity to enter into the program",
      "line": 288
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2058: an equal opportunity to enter into the program",
      "line": 290
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2059: an equal opportunity to enter into the program",
      "line": 292
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2060: an equal opportunity to enter into the program",
      "line": 294
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2061: an equal opportunity to enter into the program",
      "line": 296
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2062: an equal opportunity to enter into the program",
      "line": 298
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2063: an equal opportunity to enter into the program",
      "line": 300
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2064: an equal opportunity to enter into the program",
      "line": 302
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2065: an equal opportunity to enter into the program",
      "line": 304
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2066: an equal opportunity to enter into the program",
      "line": 306
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2067: an equal opportunity to enter into the program",
      "line": 308
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2068: an equal opportunity to enter into the program",
      "line": 310
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2069: an equal opportunity to enter into the program",
      "line": 312
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2070: an equal opportunity to enter into the program",
      "line": 314
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2071: an equal opportunity to enter into the program",
      "line": 316
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2072: an equal opportunity to enter into the program",
      "line": 318
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2073: an equal opportunity to enter into the program",
      "line": 320
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2074: an equal opportunity to enter into the program",
      "line": 322
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2075: an equal opportunity to enter into the program",
      "line": 324
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2076: an equal opportunity to enter into the program",
      "line": 326
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2077: an equal opportunity to enter into the program",
      "line": 328
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2078: an equal opportunity to enter into the program",
      "line": 330
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2079: an equal opportunity to enter into the program",
      "line": 332
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2080: an equal opportunity to enter into the program",
      "line": 334
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2081: an equal opportunity to enter into the program",
      "line": 336
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2082: an equal opportunity to enter into the program",
      "line": 338
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2083: an equal opportunity to enter into the program",
      "line": 340
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2084: an equal opportunity to enter into the program",
      "line": 342
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2085: an equal opportunity to enter into the program",
      "line": 344
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2086: an equal opportunity to enter into the program",
      "line": 346
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2087: an equal opportunity to enter into the program",
      "line": 348
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2088: an equal opportunity to enter into the program",
      "line": 350
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2089: an equal opportunity to enter into the program",
      "line": 352
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2090: an equal opportunity to enter into the program",
      "line": 354
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2091: an equal opportunity to enter into the program",
      "line": 356
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2092: an equal opportunity to enter into the program",
      "line": 358
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2093: an equal opportunity to enter into the program",
      "line": 360
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2094: an equal opportunity to enter into the program",
      "line": 362
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2095: an equal opportunity to enter into the program",
      "line": 364
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2096: an equal opportunity to enter into the program",
      "line": 366
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2097: an equal opportunity to enter into the program",
      "line": 368
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2098: an equal opportunity to enter into the program",
      "line": 370
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2099: an equal opportunity to enter into the program",
      "line": 372
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2010: an equal opportunity to enter into the program",
      "line": 374
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2011: an equal opportunity to enter into the program",
      "line": 376
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2012: an equal opportunity to enter into the program",
      "line": 378
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2013: an equal opportunity to enter into the program",
      "line": 380
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2014: an equal opportunity to enter into the program",
      "line": 382
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2015: an equal opportunity to enter into the program",
      "line": 384
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2016: an equal opportunity to enter into the program",
      "line": 386
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2017: an equal opportunity to enter into the program",
      "line": 388
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2018: an equal opportunity to enter into the program",
      "line": 390
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2019: an equal opportunity to enter into the program",
      "line": 392
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2020: an equal opportunity to enter into the program",
      "line": 394
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2021: an equal opportunity to enter into the program",
      "line": 396
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2022: an equal opportunity to enter into the program",
      "line": 398
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2023: an equal opportunity to enter into the program",
      "line": 400
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2024: an equal opportunity to enter into the program",
      "line": 402
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2025: an equal opportunity to enter into the program",
      "line": 404
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2026: an equal opportunity to enter into the program",
      "line": 406
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2027: an equal opportunity to enter into the program",
      "line": 408
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2028: an equal opportunity to enter into the program",
      "line": 410
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2029: an equal opportunity to enter into the program",
      "line": 412
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2030: an equal opportunity to enter into the program",
      "line": 414
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2031: an equal opportunity to enter into the program",
      "line": 416
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2032: an equal opportunity to enter into the program",
      "line": 418
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2033: an equal opportunity to enter into the program",
      "line": 420
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2034: an equal opportunity to enter into the program",
      "line": 422
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2035: an equal opportunity to enter into the program",
      "line": 424
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2036: an equal opportunity to enter into the program",
      "line": 426
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2037: an equal opportunity to enter into the program",
      "line": 428
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2038: an equal opportunity to enter into the program",
      "line": 430
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2039: an equal opportunity to enter into the program",
      "line": 432
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2040: an equal opportunity to enter into the program",
      "line": 434
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2041: an equal opportunity to enter into the program",
      "line": 436
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2042: an equal opportunity to enter into the program",
      "line": 438
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2043: an equal opportunity to enter into the program",
      "line": 440
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2044: an equal opportunity to enter into the program",
      "line": 442
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2045: an equal opportunity to enter into the program",
      "line": 444
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2046: an equal opportunity to enter into the program",
      "line": 446
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2047: an equal opportunity to enter into the program",
      "line": 448
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2048: an equal opportunity to enter into the program",
      "line": 450
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2049: an equal opportunity to enter into the program",
      "line": 452
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2050: an equal opportunity to enter into the program",
      "line": 454
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2051: an equal opportunity to enter into the program",
      "line": 456
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2052: an equal opportunity to enter into the program",
      "line": 458
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2053: an equal opportunity to enter into the program",
      "line": 460
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2054: an equal opportunity to enter into the program",
      "line": 462
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2055: an equal opportunity to enter into the program",
      "line": 464
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2056: an equal opportunity to enter into the program",
      "line": 466
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2057: an equal opportunity to enter into the program",
      "line": 468
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2058: an equal opportunity to enter into the program",
      "line": 470
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2059: an equal opportunity to enter into the program",
      "line": 472
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2060: an equal opportunity to enter into the program",
      "line": 474
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2061: an equal opportunity to enter into the program",
      "line": 476
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2062: an equal opportunity to enter into the program",
      "line": 478
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2063: an equal opportunity to enter into the program",
      "line": 480
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2064: an equal opportunity to enter into the program",
      "line": 482
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2065: an equal opportunity to enter into the program",
      "line": 484
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2066: an equal opportunity to enter into the program",
      "line": 486
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2067: an equal opportunity to enter into the program",
      "line": 488
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2068: an equal opportunity to enter into the program",
      "line": 490
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2069: an equal opportunity to enter into the program",
      "line": 492
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2070: an equal opportunity to enter into the program",
      "line": 494
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2071: an equal opportunity to enter into the program",
      "line": 496
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2072: an equal opportunity to enter into the program",
      "line": 498
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2073: an equal opportunity to enter into the program",
      "line": 500
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2074: an equal opportunity to enter into the program",
      "line": 502
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2075: an equal opportunity to enter into the program",
      "line": 504
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2076: an equal opportunity to enter into the program",
      "line": 506
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2077: an equal opportunity to enter into the program",
      "line": 508
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2078: an equal opportunity to enter into the program",
      "line": 510
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2079: an equal opportunity to enter into the program",
      "line": 512
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2080: an equal opportunity to enter into the program",
      "line": 514
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2081: an equal opportunity to enter into the program",
      "line": 516
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2082: an equal opportunity to enter into the program",
      "line": 518
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2083: an equal opportunity to enter into the program",
      "line": 520
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2084: an equal opportunity to enter into the program",
      "line": 522
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2085: an equal opportunity to enter into the program",
      "line": 524
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2086: an equal opportunity to enter into the program",
      "line": 526
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2087: an equal opportunity to enter into the program",
      "line": 528
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2088: an equal opportunity to enter into the program",
      "line": 530
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2089: an equal opportunity to enter into the program",
      "line": 532
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2090: an equal opportunity to enter into the program",
      "line": 534
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2091: an equal opportunity to enter into the program",
      "line": 536
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2092: an equal opportunity to enter into the program",
      "line": 538
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2093: an equal opportunity to enter into the program",
      "line": 540
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2094: an equal opportunity to enter into the program",
      "line": 542
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2095: an equal opportunity to enter into the program",
      "line": 544
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2096: an equal opportunity to enter into the program",
      "line": 546
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2097: an equal opportunity to enter into the program",
      "line": 548
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2098: an equal opportunity to enter into the program",
      "line": 550
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2099: an equal opportunity to enter into the program",
      "line": 552
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2010: an equal opportunity to enter into the program",
      "line": 554
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2011: an equal opportunity to enter into the program",
      "line": 556
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2012: an equal opportunity to enter into the program",
      "line": 558
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2013: an equal opportunity to enter into the program",
      "line": 560
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2014: an equal opportunity to enter into the program",
      "line": 562
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2015: an equal opportunity to enter into the program",
      "line": 564
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2016: an equal opportunity to enter into the program",
      "line": 566
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2017: an equal opportunity to enter into the program",
      "line": 568
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2018: an equal opportunity to enter into the program",
      "line": 570
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2019: an equal opportunity to enter into the program",
      "line": 572
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2020: an equal opportunity to enter into the program",
      "line": 574
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2021: an equal opportunity to enter into the program",
      "line": 576
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2022: an equal opportunity to enter into the program",
      "line": 578
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2023: an equal opportunity to enter into the program",
      "line": 580
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2024: an equal opportunity to enter into the program",
      "line": 582
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2025: an equal opportunity to enter into the program",
      "line": 584
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2026: an equal opportunity to enter into the program",
      "line": 586
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2027: an equal opportunity to enter into the program",
      "line": 588
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2028: an equal opportunity to enter into the program",
      "line": 590
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2029: an equal opportunity to enter into the program",
      "line": 592
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2030: an equal opportunity to enter into the program",
      "line": 594
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2031: an equal opportunity to enter into the program",
      "line": 596
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2032: an equal opportunity to enter into the program",
      "line": 598
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2033: an equal opportunity to enter into the program",
      "line": 600
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2034: an equal opportunity to enter into the program",
      "line": 602
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2035: an equal opportunity to enter into the program",
      "line": 604
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2036: an equal opportunity to enter into the program",
      "line": 606
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2037: an equal opportunity to enter into the program",
      "line": 608
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2038: an equal opportunity to enter into the program",
      "line": 610
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2039: an equal opportunity to enter into the program",
      "line": 612
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2040: an equal opportunity to enter into the program",
      "line": 614
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2041: an equal opportunity to enter into the program",
      "line": 616
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2042: an equal opportunity to enter into the program",
      "line": 618
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2043: an equal opportunity to enter into the program",
      "line": 620
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2044: an equal opportunity to enter into the program",
      "line": 622
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2045: an equal opportunity to enter into the program",
      "line": 624
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2046: an equal opportunity to enter into the program",
      "line": 626
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2047: an equal opportunity to enter into the program",
      "line": 628
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2048: an equal opportunity to enter into the program",
      "line": 630
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2049: an equal opportunity to enter into the program",
      "line": 632
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2050: an equal opportunity to enter into the program",
      "line": 634
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2051: an equal opportunity to enter into the program",
      "line": 636
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2052: an equal opportunity to enter into the program",
      "line": 638
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2053: an equal opportunity to enter into the program",
      "line": 640
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2054: an equal opportunity to enter into the program",
      "line": 642
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2055: an equal opportunity to enter into the program",
      "line": 644
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2056: an equal opportunity to enter into the program",
      "line": 646
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2057: an equal opportunity to enter into the program",
      "line": 648
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2058: an equal opportunity to enter into the program",
      "line": 650
    },
    {
      "type": "heading",
      "level": 2,
      "section": "2059: an equal opportunity to enter into the program",
      "line": 652
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20510: an equal opportunity to enter into the program",
      "line": 654
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 656
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 658
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 660
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 662
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 664
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 666
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 668
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20518: an equal opportunity to enter into the program",
      "line": 670
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20519: an equal opportunity to enter into the program",
      "line": 672
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20520: an equal opportunity to enter into the program",
      "line": 674
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 676
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20518: an equal opportunity to enter into the program",
      "line": 678
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20519: an equal opportunity to enter into the program",
      "line": 680
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20521: an equal opportunity to enter into the program",
      "line": 682
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20510: an equal opportunity to enter into the program",
      "line": 684
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 686
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 688
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 690
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 692
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 694
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 696
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 698
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20518: an equal opportunity to enter into the program",
      "line": 700
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20519: an equal opportunity to enter into the program",
      "line": 702
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20510: an equal opportunity to enter into the program",
      "line": 704
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 706
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 708
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 710
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 712
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 714
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 716
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 718
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20518: an equal opportunity to enter into the program",
      "line": 720
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20519: an equal opportunity to enter into the program",
      "line": 722
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20510: an equal opportunity to enter into the program",
      "line": 724
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 726
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 728
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 730
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 732
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 734
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 736
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 738
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20518: an equal opportunity to enter into the program",
      "line": 740
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20519: an equal opportunity to enter into the program",
      "line": 742
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 744
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 746
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 748
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 750
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 752
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 754
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 756
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20518: an equal opportunity to enter into the program",
      "line": 758
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20519: an equal opportunity to enter into the program",
      "line": 760
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 762
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 764
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 766
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 768
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 770
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 772
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 774
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 776
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 778
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 780
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 782
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 784
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 786
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 788
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 790
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 792
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 794
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 796
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 798
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 800
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 802
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 804
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 806
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 808
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 810
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 812
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 814
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 816
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 818
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 820
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 822
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 824
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 826
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 828
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 830
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 832
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20517: an equal opportunity to enter into the program",
      "line": 834
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 836
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 838
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 840
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 842
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 844
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 846
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 848
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 850
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 852
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 854
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 856
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20516: an equal opportunity to enter into the program",
      "line": 858
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 860
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 862
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 864
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 866
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 868
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 870
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 872
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 874
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 876
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20513: an equal opportunity to enter into the program",
      "line": 878
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 880
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 882
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20514: an equal opportunity to enter into the program",
      "line": 884
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20515: an equal opportunity to enter into the program",
      "line": 886
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 888
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 890
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 892
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 894
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 896
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 898
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 900
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20511: an equal opportunity to enter into the program",
      "line": 902
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 904
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 906
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 908
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 910
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 912
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 914
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 916
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 918
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 920
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 922
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 924
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 926
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 928
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 930
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 932
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 934
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 936
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 938
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 940
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 942
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 944
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 946
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 948
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 950
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 952
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 954
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 956
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 958
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 960
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 962
    },
    {
      "type": "heading",
      "level": 2,
      "section": "20512: an equal opportunity to enter into the program",
      "line": 964
    },
    {
      "type": "text",
      "section": "20512: an equal opportunity to enter into the program",
      "line": 968,
      "preview": "--- page 2 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 970
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 972,
      "preview": "|  Webinar Topic | CE Credit Deadline*  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 973,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 974,
      "preview": "|  Fluids and Electrolytes | August 30, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 975,
      "preview": "|  Parenteral Nutrition (PN) and Home PN | September 6, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 976,
      "preview": "|  Nutrient Deficiencies and Malnutrition Assessment | September 13, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 977,
      "preview": "|  Enteral Nutrition (EN) and Home EN | September 19, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 978,
      "preview": "|  Enteral Nutrition and Parenteral Nutrition Access | September 27, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 979,
      "preview": "|  Gastrointestinal (GI) Disorders | October 4, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 980,
      "preview": "|  Acid Base | October 10, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 981,
      "preview": "|  Critical Care and Statistics | October 12, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 982,
      "preview": "|  Ethics for the Nutrition Professional | October 17, 2025  |"
    },
    {
      "type": "table",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 983,
      "preview": "|  Pediatric and Neonatal Nutrition Support | October 19, 2025  |"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 985,
      "preview": "*Please note that CE credit cannot be claimed after the deadline"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit Deadlines",
      "line": 987,
      "preview": "--- page 3 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025 CE Credit - Important Information",
      "line": 989
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Please note the following:",
      "line": 991
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 993,
      "preview": "- CE credit CANNOT be claimed for missed webinars. You must attend the live webinar broadcast at the"
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 994,
      "preview": "- CE Credit is calculated on a per webinar attended basis. If you miss a webinar, you can still rece"
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 995,
      "preview": "- CE credit will be granted for each webinar attended up to a maximum of 15.5 CE credits for the ent"
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 996,
      "preview": "- You must complete the evaluation after each webinar to receive CE credit for that webinar."
    },
    {
      "type": "text",
      "section": "Please note the following:",
      "line": 997,
      "preview": "- You must complete the Overall Conference Evaluation to receive your course certificate. This form "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 1000
    },
    {
      "type": "text",
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 1002,
      "preview": "Due to Accreditation Council for Pharmacy Education (ACPE) and National Association of Boards of Pha"
    },
    {
      "type": "text",
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 1004,
      "preview": "Pharmacy participants are required to submit their birthdate (MM/DD), submit their NABP ID \\#, and c"
    },
    {
      "type": "text",
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 1006,
      "preview": "ASPEN is not responsible for late or incorrect submissions by the participant."
    },
    {
      "type": "text",
      "section": "IMPORTANT INFORMATION FOR PHARMACY PARTICIPANTS! Pharmacy participants should claim CE credit as soon as possible following each session attended.",
      "line": 1008,
      "preview": "--- page 4 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Claim CE Credit",
      "line": 1010
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Log into eLearning Center",
      "line": 1012
    },
    {
      "type": "text",
      "section": "Log into eLearning Center",
      "line": 1014,
      "preview": "Step 1: Log into the ASPEN eLearning Center at https://aspen.digitellinc.com."
    },
    {
      "type": "text",
      "section": "Log into eLearning Center",
      "line": 1015,
      "preview": "(Your login is the same email and password you use for the main ASPEN website.)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "To Claim CE Credit",
      "line": 1017
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 1019,
      "preview": "Step 2: Click on the \"My Account\" button at the top right of the screen."
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 1020,
      "preview": "Step 3: Click \"Live Events\" in the dropdown menu."
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 1021,
      "preview": "Step 4: Find the Nutrition Support Fundamentals Course Summer 2025. Under the course title and dates"
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 1023,
      "preview": "Step 5: Click on \"Evaluations\" in the menu under the course title and dates."
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 1024,
      "preview": "Step 6: Click on the \"Take Evaluation\" button under the appropriate session heading."
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 1025,
      "preview": "After completing the evaluation, you should see a statement of completion with the date and time. Th"
    },
    {
      "type": "text",
      "section": "To Claim CE Credit",
      "line": 1027,
      "preview": "--- page 5 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1029
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1030,
      "preview": "How to View CE Credit and Access CE Transcript"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1032,
      "preview": "To View CE Credit"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1033,
      "preview": "Step 1: Click on the \"My Account\" button at the top right of the screen."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1035,
      "preview": "Step 2: Click \"CE Transcript\" in the dropdown menu."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1037,
      "preview": "Step 3: Find the Nutrition Support Fundamentals Course Summer 2025 and click on the Course Title. Yo"
    },
    {
      "type": "image",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1039,
      "content": "![img-1.jpeg](images/9fc704712b53fa33.png)"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1041,
      "preview": "To Access CE Transcript"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1042,
      "preview": "Please note that you will not be able to print your CE transcript until the end of the course. After"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1044,
      "preview": "Complete steps 1-3 above."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1046,
      "preview": "Click on the \"Overall Evaluation\" button at the bottom of the course information and complete the ov"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1048,
      "preview": "A button that says \"Print Transcript\" should appear at the bottom of the course information. Click o"
    },
    {
      "type": "image",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1050,
      "content": "![img-2.jpeg](images/251f5267803c3999.png)"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025",
      "line": 1052,
      "preview": "--- page 6 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1054
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1056,
      "preview": "Step 1: Log into the ASPEN eLearning Center at https://aspen.digitellinc.com. (Your login is the sam"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1058,
      "preview": "Step 2: Click on the \"My Account\" button at the top right of the screen."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1059,
      "preview": "Step 3: Click \"Live Events\" in the dropdown menu."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1060,
      "preview": "Step 4: Find Nutrition Support Fundamentals Course Summer 2025. Under the course title and dates, cl"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1062,
      "preview": "Step 5: Click on \"Recordings\" in the menu under the course title and dates."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1063,
      "preview": "Step 6: Find the appropriate webinar session and click on the \"View Archive\" button."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1064,
      "preview": "To listen to the recording, click inside the webinar player."
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1065,
      "preview": "To download the recording, click \"Download MP3\" underneath the webinar player on the right side of t"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1067,
      "preview": "To download the handouts, click on the \"Download Handout\" underneath the webinar player on the right"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1068,
      "preview": "*The webinar recording will be available in the eLearning Center within 3 business days following th"
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1069,
      "preview": "**If you miss the live webinar broadcast, you can still access the webinar handout and recording in "
    },
    {
      "type": "text",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1071,
      "preview": "--- page 7 ---"
    },
    {
      "type": "image",
      "section": "Nutrition Support Fundamentals Course: Summer 2025 How to Access Recording and Handout",
      "line": 1073,
      "content": "![img-3.jpeg](images/d3048a843d14c5ff.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Nutrition Support Fundamentals Course",
      "line": 1075
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Fluids and Electrolytes",
      "line": 1077
    },
    {
      "type": "text",
      "section": "Fluids and Electrolytes",
      "line": 1079,
      "preview": "**July 30, 2025 3:00 \u2013 4:30 PM ET**"
    },
    {
      "type": "image",
      "section": "Fluids and Electrolytes",
      "line": 1081,
      "content": "![img-4.jpeg](images/16acf253d431af6a.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Using the Webinar Player",
      "line": 1083
    },
    {
      "type": "image",
      "section": "Using the Webinar Player",
      "line": 1085,
      "content": "![img-5.jpeg](images/0c1de0c6701c5b8b.png)"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 1087,
      "preview": "Click on the tabs on the left side of your screen to access the webinar player functions."
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 1089,
      "preview": "- **Info Panel**: View session and presenter information"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 1090,
      "preview": "- **Chat**: Communicate with other session attendees"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 1091,
      "preview": "- **Polling**: Answer polling questions"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 1092,
      "preview": "- **Resources**: Download handout and reference material"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 1093,
      "preview": "- **Questions**: Submit questions for presenters"
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 1095,
      "preview": "For technical assistance, click Request Support."
    },
    {
      "type": "text",
      "section": "Using the Webinar Player",
      "line": 1097,
      "preview": "--- page 8 ---"
    },
    {
      "type": "image",
      "section": "Using the Webinar Player",
      "line": 1099,
      "content": "![img-6.jpeg](images/1cc4c287224e21c0.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Anne Tucker, PharmD, BCNSP, FASPEN",
      "line": 1101
    },
    {
      "type": "text",
      "section": "Anne Tucker, PharmD, BCNSP, FASPEN",
      "line": 1103,
      "preview": "Clinical Pharmacy Specialist - Critical Care/Nutrition Support"
    },
    {
      "type": "text",
      "section": "Anne Tucker, PharmD, BCNSP, FASPEN",
      "line": 1104,
      "preview": "The University of Texas MD Anderson Cancer Center"
    },
    {
      "type": "text",
      "section": "Anne Tucker, PharmD, BCNSP, FASPEN",
      "line": 1105,
      "preview": "Houston, Texas"
    },
    {
      "type": "image",
      "section": "Anne Tucker, PharmD, BCNSP, FASPEN",
      "line": 1107,
      "content": "![img-7.jpeg](images/87623ed6046d8d26.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Disclosures",
      "line": 1109
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 1111,
      "preview": "Consultant for Up To Date, Inc."
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 1113,
      "preview": "I attest that clinical recommendations are evidence-based and free of commercial bias (e.g., peer-re"
    },
    {
      "type": "image",
      "section": "Disclosures",
      "line": 1115,
      "content": "![img-8.jpeg](images/4cb8965dafa3e7ca.png)"
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 1117,
      "preview": "--- page 9 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Learning Objectives",
      "line": 1119
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1121,
      "preview": "Upon completion of this session, the learner will be able to:"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1123,
      "preview": "- Assess fluid and electrolyte needs of a patient"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1124,
      "preview": "- Develop a therapeutic plan for fluid and electrolyte requirements"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 1125,
      "preview": "- Prevent and manage complications of fluid and electrolyte abnormalities"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Fluids",
      "line": 1128
    },
    {
      "type": "text",
      "section": "Fluids",
      "line": 1130,
      "preview": "--- page 10 ---"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Total Body Water (TBW)",
      "line": 1132
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1134,
      "preview": "- Water content of the body"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1135,
      "preview": "- Decreases with increasing age"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1136,
      "preview": "- 75-80% lean body mass (LBM) for infants"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1137,
      "preview": "- 60% LBM for children"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1138,
      "preview": "- 60% LBM for males (< 70 y/o)"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1139,
      "preview": "- 50% LBM for females & elderly males (> 70 y/o)"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1140,
      "preview": "- 45% LBM for elderly females (> 70 y/o)"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1141,
      "preview": "- Affected by body composition"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1142,
      "preview": "- Water content of fat ~10%"
    },
    {
      "type": "text",
      "section": "Total Body Water (TBW)",
      "line": 1143,
      "preview": "- Water content of muscle mass ~75-80%"
    },
    {
      "type": "image",
      "section": "Total Body Water (TBW)",
      "line": 1145,
      "content": "![img-9.jpeg](images/080549db89524ada.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1147
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1149,
      "preview": "|   | Average Daily"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1150,
      "preview": "Volume (mL) |  | Average Daily"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1151,
      "preview": "Volume (mL)  |"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1152,
      "preview": "| --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1153,
      "preview": "|  Water gain |  | Water loss |   |"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1154,
      "preview": "|  Sensible |  | Sensible |   |"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1155,
      "preview": "|  Oral fluid | 800 \u2013 1500 | Urine | 800 - 1500  |"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1156,
      "preview": "|  Solid food | 500 - 700 | Gastrointestinal | 0 - 250  |"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1157,
      "preview": "|  Insensible |  | Insensible |   |"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1158,
      "preview": "|  Water oxidation | 250 | Lungs/skin | 600 - 900  |"
    },
    {
      "type": "table",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1159,
      "preview": "|  **TOTAL** | **1500 - 2500** | **TOTAL** | **1500 - 2500**  |"
    },
    {
      "type": "image",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1161,
      "content": "![img-10.jpeg](images/311ea2f29c046820.png)"
    },
    {
      "type": "text",
      "section": "Water Exchange \u2013 60-80 kg patient",
      "line": 1163,
      "preview": "--- page 11 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Maintenance Fluid Requirements",
      "line": 1165
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements",
      "line": 1167,
      "preview": "- Holliday-Segar formula (generally used for pediatrics)"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements",
      "line": 1168,
      "preview": "- $100 \\mathrm{~mL} / \\mathrm{kg}$ for the first 10 kg , then ADD"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements",
      "line": 1169,
      "preview": "- $50 \\mathrm{~mL} / \\mathrm{kg}$ for the second 10 kg , then ADD"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements",
      "line": 1170,
      "preview": "- $20 \\mathrm{~mL} / \\mathrm{kg}$ for each $\\mathrm{kg}>20 \\mathrm{~kg}$"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements",
      "line": 1171,
      "preview": "- Adjusted Holliday-Segar formula"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements",
      "line": 1172,
      "preview": "- 1500 mL for the first 20 kg of body weight, then ADD"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements",
      "line": 1173,
      "preview": "- Ages $\\leq 50$ years: 20 mL per kg of remaining body weight"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements",
      "line": 1174,
      "preview": "- Ages $>50$ years: 15 mL per kg of remaining body weight"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1177
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1179,
      "preview": "- Weight and age-based formula"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1180,
      "preview": "- Ages 18-55 years: $35 \\mathrm{~mL} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1181,
      "preview": "- Ages 56-75 years: $30 \\mathrm{~mL} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1182,
      "preview": "- Ages $>75$ years: $25 \\mathrm{~mL} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1183,
      "preview": "- Fluid-restricted adults: $\\leq 25 \\mathrm{~mL} / \\mathrm{kg} /$ day"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1184,
      "preview": "- $1 \\mathrm{~mL} / \\mathrm{kcal}$ ingested"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1185,
      "preview": "- 1500-1600 mL/m\u00b2 per 24 hours"
    },
    {
      "type": "text",
      "section": "Maintenance Fluid Requirements, cont.",
      "line": 1187,
      "preview": "--- page 12 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Calculating Fluid Requirements",
      "line": 1189
    },
    {
      "type": "text",
      "section": "Calculating Fluid Requirements",
      "line": 1191,
      "preview": "- 65 year old male \u2013 70 kg"
    },
    {
      "type": "table",
      "section": "Calculating Fluid Requirements",
      "line": 1193,
      "preview": "|  **Holliday-Segar formula** | **Adjusted Holliday-Segar formula** | **Weight and age based formula"
    },
    {
      "type": "table",
      "section": "Calculating Fluid Requirements",
      "line": 1194,
      "preview": "| --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Calculating Fluid Requirements",
      "line": 1195,
      "preview": "|  100 mL/kg x 10 kg = 1000 mL | 1500 mL for first 20 kg | Since 65 years old,  |"
    },
    {
      "type": "table",
      "section": "Calculating Fluid Requirements",
      "line": 1196,
      "preview": "|  50 mL/kg x 10 kg = 500 mL | Since > 50 year old, ADD | 30 mL/kg x 70 kg = 2100 mL/day  |"
    },
    {
      "type": "table",
      "section": "Calculating Fluid Requirements",
      "line": 1197,
      "preview": "|  20 mL/kg x 50 kg = 1000 mL | 15 mL/kg x 50 kg = 750 mL | Divide by 24 hours for infusion rate  |"
    },
    {
      "type": "table",
      "section": "Calculating Fluid Requirements",
      "line": 1198,
      "preview": "|  Add together = 2500 mL/day | Add together = 2250 mL/day |   |"
    },
    {
      "type": "table",
      "section": "Calculating Fluid Requirements",
      "line": 1199,
      "preview": "|  Divide by 24 hours for infusion rate | Divide by 24 hours for infusion rate |   |"
    },
    {
      "type": "image",
      "section": "Calculating Fluid Requirements",
      "line": 1201,
      "content": "![img-11.jpeg](images/c36d4cd9f2d0a556.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Factors that Alter Fluid Needs",
      "line": 1203
    },
    {
      "type": "heading",
      "level": 2,
      "section": "MORE",
      "line": 1205
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1207,
      "preview": "- Fever*"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1208,
      "preview": "- Vomiting / NG output"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1209,
      "preview": "- Diarrhea"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1210,
      "preview": "- Ostomy / fistula output"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1211,
      "preview": "- Hyperventilation (10-60%)"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1212,
      "preview": "- Excessive sweating (10-25%)"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1213,
      "preview": "- Burn injury"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1214,
      "preview": "- Prematurity"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1216,
      "preview": "*12.5% for each 1\u00b0 C above normal"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1218,
      "preview": "- NG, nasogastric"
    },
    {
      "type": "text",
      "section": "MORE",
      "line": 1219,
      "preview": "- SIADH, syndrome of inappropriate antidiuretic hormone"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "LESS",
      "line": 1221
    },
    {
      "type": "text",
      "section": "LESS",
      "line": 1223,
      "preview": "- Fluid overload"
    },
    {
      "type": "text",
      "section": "LESS",
      "line": 1224,
      "preview": "- Heart failure"
    },
    {
      "type": "text",
      "section": "LESS",
      "line": 1225,
      "preview": "- Renal failure"
    },
    {
      "type": "text",
      "section": "LESS",
      "line": 1226,
      "preview": "- SIADH"
    },
    {
      "type": "text",
      "section": "LESS",
      "line": 1227,
      "preview": "- Ascites"
    },
    {
      "type": "text",
      "section": "LESS",
      "line": 1228,
      "preview": "- Anasarca"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "ASPIR",
      "line": 1230
    },
    {
      "type": "text",
      "section": "ASPIR",
      "line": 1232,
      "preview": "- LEADING THE SEGNATE AND PRACTICE OF CLINICAL NUTRITION"
    },
    {
      "type": "text",
      "section": "ASPIR",
      "line": 1233,
      "preview": "- American Society for Parenteral and Enteral Nutrition"
    },
    {
      "type": "text",
      "section": "ASPIR",
      "line": 1235,
      "preview": "--- page 13 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1237
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1239,
      "preview": "$1,000 \\mathrm{~mL}$ urine output"
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1240,
      "preview": "Add 500 mL for insensible loss"
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1241,
      "preview": "Add net GI loss (mL) or subtract net GI gain (mL)"
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1243,
      "preview": "Oral Intake 1,000 mL"
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1244,
      "preview": "Stoma out $1,500 \\mathrm{~mL}$"
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1245,
      "preview": "Net GI Loss 500 mL"
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1247,
      "preview": "Oral Intake 1,000 mL"
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1248,
      "preview": "GI loss 0 mL"
    },
    {
      "type": "text",
      "section": "Estimating Minimal Adult IV Fluid Needs",
      "line": 1249,
      "preview": "Net GI Gain 1,000 mL"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Evaluating Fluid and Sodium Status",
      "line": 1251
    },
    {
      "type": "text",
      "section": "Evaluating Fluid and Sodium Status",
      "line": 1253,
      "preview": "- History and Physical Exam"
    },
    {
      "type": "text",
      "section": "Evaluating Fluid and Sodium Status",
      "line": 1254,
      "preview": "- Vital Signs"
    },
    {
      "type": "text",
      "section": "Evaluating Fluid and Sodium Status",
      "line": 1255,
      "preview": "- Daily Weights"
    },
    {
      "type": "text",
      "section": "Evaluating Fluid and Sodium Status",
      "line": 1256,
      "preview": "- Intake and Output Records"
    },
    {
      "type": "text",
      "section": "Evaluating Fluid and Sodium Status",
      "line": 1257,
      "preview": "- Serum electrolytes, BUN, Cr and osmolality"
    },
    {
      "type": "text",
      "section": "Evaluating Fluid and Sodium Status",
      "line": 1258,
      "preview": "- Urine Na, urine specific gravity, urine osmolality"
    },
    {
      "type": "text",
      "section": "Evaluating Fluid and Sodium Status",
      "line": 1260,
      "preview": "--- page 14 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Fluid Volume Assessment",
      "line": 1262
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Fluid Deficit",
      "line": 1264
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1266,
      "preview": "- Decreased skin turgor"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1267,
      "preview": "- Dry mucous membrane"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1268,
      "preview": "- Weight loss"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1269,
      "preview": "- Sunken eyes / dark circles"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1270,
      "preview": "- Orthostasis ( $\\downarrow$ BP / $\\uparrow$ HR)"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1271,
      "preview": "- Oliguria"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1272,
      "preview": "- BUN / Cr ratio > 15"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1273,
      "preview": "- Elevated hematocrit"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1274,
      "preview": "- Elevated urine specific gravity"
    },
    {
      "type": "text",
      "section": "Fluid Deficit",
      "line": 1275,
      "preview": "- Urine $\\mathrm{Na}<20 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Fluid Overload",
      "line": 1278
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1280,
      "preview": "- Edema"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1281,
      "preview": "- Ascites"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1282,
      "preview": "- Weight gain"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1283,
      "preview": "- Rales / crackles on chest auscultation"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1284,
      "preview": "- Pulmonary edema / effusions"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1285,
      "preview": "- Elevated jugular venous pressure"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1287,
      "preview": "BP, blood pressure; HR, heart rate"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1288,
      "preview": "aspen"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1289,
      "preview": "LEADING THE SCIENCE AND"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1290,
      "preview": "PRACTICE OF SURVEYS, NUTRITION"
    },
    {
      "type": "text",
      "section": "Fluid Overload",
      "line": 1291,
      "preview": "American Society for Parenteral and Enteral Nutrition"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Selection of Fluid Choice",
      "line": 1293
    },
    {
      "type": "text",
      "section": "Selection of Fluid Choice",
      "line": 1295,
      "preview": "- Evaluate patient condition"
    },
    {
      "type": "text",
      "section": "Selection of Fluid Choice",
      "line": 1296,
      "preview": "- Crystalloid vs. colloid"
    },
    {
      "type": "text",
      "section": "Selection of Fluid Choice",
      "line": 1297,
      "preview": "- Crystalloid differences by solution tonicity (and additional electrolytes if present)"
    },
    {
      "type": "text",
      "section": "Selection of Fluid Choice",
      "line": 1298,
      "preview": "- Maintenance fluids - hypotonic (typically $1 / 2$ NS concentration)"
    },
    {
      "type": "text",
      "section": "Selection of Fluid Choice",
      "line": 1299,
      "preview": "- Resuscitation fluids - isotonic (NS, Lactated Ringers, Plasmalyte)"
    },
    {
      "type": "text",
      "section": "Selection of Fluid Choice",
      "line": 1300,
      "preview": "- Replacement fluids - geared to the type of fluid lost"
    },
    {
      "type": "text",
      "section": "Selection of Fluid Choice",
      "line": 1302,
      "preview": "--- page 15 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Composition of Plasma & Crystalloids",
      "line": 1304
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1306,
      "preview": "|   |  | mEq/L |  |  |  |  |   |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1307,
      "preview": "| --- | --- | --- | --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1308,
      "preview": "|  Fluid | Tonicity | Na | Cl | K | Ca | Mg | Buffers  |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1309,
      "preview": "|  Plasma | Isotonic | 140 | 103 | 4 | 5 | 2 | Bicarb (25)  |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1310,
      "preview": "|  D5W | Hypotonic | - | - | - | - | - | -  |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1311,
      "preview": "|  0.225% NaCl | Hypotonic | 38 | 38 | - | - | - | -  |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1312,
      "preview": "|  0.45% NaCl | Hypotonic | 77 | 77 | - | - | - | -  |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1313,
      "preview": "|  0.9% NaCl | Isotonic | 154 | 154 | - | - | - | -  |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1314,
      "preview": "|  Lactated Ringer's | Isotonic | 130 | 109 | 4 | 3 | - | Lactate (28)  |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1315,
      "preview": "|  Plasma-Lyte | Isotonic | 140 | 98 | 5 | - | 3 | Acetate (27)  |"
    },
    {
      "type": "table",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1316,
      "preview": "|  3% NaCl | Hypertonic | 513 | 513 | - | - | - | -  |"
    },
    {
      "type": "text",
      "section": "Composition of Plasma & Crystalloids",
      "line": 1318,
      "preview": "Adapted from: Mario PL. Colloid and Crystalloid Resuscitation. In: *The ICU Book*, 2007 ed. Philadel"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Gastrointestinal Losses",
      "line": 1320
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1322,
      "preview": "|  Body Fluid Type | mEq/L |  |  |   |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1323,
      "preview": "| --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1324,
      "preview": "|   | Na | Cl | K | HCO\u2083\u207b  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1325,
      "preview": "|  Stomach | 60 | 130 | 15 | 0  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1326,
      "preview": "|  Duodenum | 140 | 80 | 5 | 0  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1327,
      "preview": "|  Pancreas | 140 | 75 | 5 | 115  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1328,
      "preview": "|  Bile | 145 | 100 | 5 | 35  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1329,
      "preview": "|  Ileum | 140 | 104 | 5 | 30  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1330,
      "preview": "|  Colon | 60 | 40 | 30 | 0  |"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Losses",
      "line": 1332,
      "preview": "Gastric fluid loss replacement 0.45% NaCl (1/2 Normal Saline) + 10-20 mEq KCl/L"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Losses",
      "line": 1334,
      "preview": "Canada TW et al. ASPEN Adult Nutrition Support Core Curriculum. 3rd ed. 2017:113-37."
    },
    {
      "type": "image",
      "section": "Gastrointestinal Losses",
      "line": 1336,
      "content": "![img-12.jpeg](images/db4d3f2ff8c12c9d.png)"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Losses",
      "line": 1338,
      "preview": "--- page 16 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Gastrointestinal Losses",
      "line": 1340
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1342,
      "preview": "|  Body Fluid Type | mEq/L |  |  |   |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1343,
      "preview": "| --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1344,
      "preview": "|   | Na | Cl | K | $\\mathrm{HCO}_{3}$  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1345,
      "preview": "|  Stomach | 60 | 130 | 15 | 0  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1346,
      "preview": "|  Duodenum | 140 | 80 | 5 | 0  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1347,
      "preview": "|  Pancreas | 140 | 75 | 5 | 115  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1348,
      "preview": "|  Bile | 145 | 100 | 5 | 35  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1349,
      "preview": "|  Ileum | 140 | 104 | 5 | 30  |"
    },
    {
      "type": "table",
      "section": "Gastrointestinal Losses",
      "line": 1350,
      "preview": "|  Colon | 60 | 40 | 30 | 0  |"
    },
    {
      "type": "text",
      "section": "Gastrointestinal Losses",
      "line": 1352,
      "preview": "Small bowel fluid loss replacement Balanced crystalloid (e.g., Ringers Lactate, Plasmalyte) Bicarbon"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Third Space Fluid Losses",
      "line": 1354
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1356,
      "preview": "- Abnormal fluid shifts from the intravascular space to the tissues"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1357,
      "preview": "- Fluid is poorly exchangeable"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1358,
      "preview": "- Tissue water is increased at expense of intravascular volume"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1359,
      "preview": "- Frequently seen with the following conditions"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1360,
      "preview": "- Intestinal obstruction or ileus"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1361,
      "preview": "- Peritonitis"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1362,
      "preview": "- Pancreatitis"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1363,
      "preview": "- Pleural effusions or ascites"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1364,
      "preview": "- Trauma"
    },
    {
      "type": "text",
      "section": "Third Space Fluid Losses",
      "line": 1366,
      "preview": "--- page 17 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Peripheral Edema",
      "line": 1368
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1370,
      "preview": "Pitting edema"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1372,
      "preview": "- Most common type"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1373,
      "preview": "- Responds to diuretics"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1374,
      "preview": "- Causes"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1375,
      "preview": "- Heart failure"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1376,
      "preview": "- Cirrhosis"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1377,
      "preview": "- Nephrotic syndrome"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1378,
      "preview": "- Pregnancy"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1379,
      "preview": "- Nutritional edema"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1380,
      "preview": "- Idiopathic edema"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1382,
      "preview": "Non-pitting edema"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1384,
      "preview": "- Disturbance of the lymphatic system (e.g., lymphedema)"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1385,
      "preview": "- Not likely to respond to diuretics"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1386,
      "preview": "- Causes"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1387,
      "preview": "- Mastectomy"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1388,
      "preview": "- Radiation"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1389,
      "preview": "- Tumors"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1390,
      "preview": "- Trauma"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1392,
      "preview": "Self-assessment Question \\#1"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1394,
      "preview": "Which of the following sodium concentrations ( $\\mathrm{mEq} / \\mathrm{L}$ ) is the most appropriate"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1395,
      "preview": "A. 38.5 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1396,
      "preview": "B. 77 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1397,
      "preview": "C. 115 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1398,
      "preview": "D. 154 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Peripheral Edema",
      "line": 1400,
      "preview": "--- page 18 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Electrolytes",
      "line": 1402
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Electrolytes",
      "line": 1404
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1406,
      "preview": "|  Electrolyte | Adult Serum Concentrations | Adult Requirements  |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1407,
      "preview": "| --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1408,
      "preview": "|  Sodium | $135-145 \\mathrm{mEq} / \\mathrm{L}$ | $1-2 \\mathrm{mEq} / \\mathrm{kg} /$ day  |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1409,
      "preview": "|  Potassium | $3.5-5 \\mathrm{mEq} / \\mathrm{L}$ | $1-2 \\mathrm{mEq} / \\mathrm{kg} /$ day  |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1410,
      "preview": "|  Chloride | $98-108 \\mathrm{mEq} / \\mathrm{L}$ | As needed to maintain acid-base balance  |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1411,
      "preview": "|  $\\mathrm{CO}_{2}$ | $23-30 \\mathrm{mEq} / \\mathrm{L}$ | As needed to maintain acid-base balance  "
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1412,
      "preview": "|  Calcium | $9-10.5 \\mathrm{mg} / \\mathrm{dL}$ | $10-15 \\mathrm{mEq} /$ day  |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1413,
      "preview": "|  Phosphorus | $2.5-4.5 \\mathrm{mg} / \\mathrm{dL}$ | $20-40 \\mathrm{mmol} /$ day  |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1414,
      "preview": "|  Magnesium | $1.7-2.4 \\mathrm{mg} / \\mathrm{dL}$ | $8-20 \\mathrm{mEq} /$ day  |"
    },
    {
      "type": "table",
      "section": "Electrolytes",
      "line": 1415,
      "preview": "|  *Variations in lab values exist between institutions |  |   |"
    },
    {
      "type": "text",
      "section": "Electrolytes",
      "line": 1417,
      "preview": "--- page 19 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Sodium (Na)",
      "line": 1419
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1421,
      "preview": "- Normal serum sodium (Na) 135 - 145 mEq or mmol / Liter"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1422,
      "preview": "- Total body Na is $40 \\mathrm{mEq} / \\mathrm{kg}(2,800 \\mathrm{mEq})$ in a 70 kg patient"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1423,
      "preview": "- One third fixed in bone"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1424,
      "preview": "- Two thirds exchangeable (mostly extracellular)"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1425,
      "preview": "- Adequate intake (AI) is $1500 \\mathrm{mg}(65 \\mathrm{mEq})$ daily"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1426,
      "preview": "- Renal Na reabsorption efficient ( $<1 \\mathrm{mEq} / \\mathrm{L}$ )"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1427,
      "preview": "- Major extracellular cation functions in regulation of extracellular fluid volume, osmolarity and m"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1429,
      "preview": "Sodium Disorders"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1431,
      "preview": "- Disorders are a result of alterations in water balance"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1432,
      "preview": "- Hyponatremia"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1433,
      "preview": "- Serum Na less than 135 mEq or mmol / Liter"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1434,
      "preview": "- Common electrolyte disorder"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1435,
      "preview": "- Hypernatremia"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1436,
      "preview": "- Serum Na greater than 145 mEq or mmol / Liter"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1437,
      "preview": "- Much less common"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1438,
      "preview": "- High morbidity and mortality"
    },
    {
      "type": "text",
      "section": "Sodium (Na)",
      "line": 1440,
      "preview": "--- page 20 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Clinical Presentation",
      "line": 1442
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1444,
      "preview": "|  |   |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1445,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1446,
      "preview": "|  **Hyponatremia** |   |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1447,
      "preview": "|  **Severity** | **Symptom**  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1448,
      "preview": "|  Moderately severe | Nausea without vomiting  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1449,
      "preview": "|   | Confusion  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1450,
      "preview": "|   | Headache  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1451,
      "preview": "|  Severe | Vomiting  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1452,
      "preview": "|   | Cardiorespiratory distress  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1453,
      "preview": "|   | Abnormal and deep somnolence  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1454,
      "preview": "|   | Seizures  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1455,
      "preview": "|   | Coma (Glasgow Coma Scale \u2264 8)  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1457,
      "preview": "|  |   |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1458,
      "preview": "| --- | --- |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1459,
      "preview": "|  **Hypernatremia** |   |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1460,
      "preview": "|  **Severity** | **Symptom**  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1461,
      "preview": "|  Mild to moderate | Lethargy  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1462,
      "preview": "|   | Weakness  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1463,
      "preview": "|   | Confusion  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1464,
      "preview": "|   | Restlessness  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1465,
      "preview": "|   | Irritability  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1466,
      "preview": "|  Severe (or rapid increase) | Twitching  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1467,
      "preview": "|   | Seizures  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1468,
      "preview": "|   | Coma  |"
    },
    {
      "type": "table",
      "section": "Clinical Presentation",
      "line": 1469,
      "preview": "|   | Death  |"
    },
    {
      "type": "image",
      "section": "Clinical Presentation",
      "line": 1471,
      "content": "![img-13.jpeg](images/ed50583e2f85e2a9.png)"
    },
    {
      "type": "image",
      "section": "Clinical Presentation",
      "line": 1473,
      "content": "![img-14.jpeg](images/749803892e8dfb7b.png)"
    },
    {
      "type": "text",
      "section": "Clinical Presentation",
      "line": 1475,
      "preview": "--- page 21 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hyponatremia Algorithm",
      "line": 1477
    },
    {
      "type": "text",
      "section": "Hyponatremia Algorithm",
      "line": 1479,
      "preview": "Plamsa osmolality ( $\\mathrm{mOsm} / \\mathrm{kg}$ ) $=$"
    },
    {
      "type": "text",
      "section": "Hyponatremia Algorithm",
      "line": 1480,
      "preview": "$2 \\times[$ serum Na$]+[$ glucose $] / 18+[$ BUN $] / 2.8$"
    },
    {
      "type": "image",
      "section": "Hyponatremia Algorithm",
      "line": 1481,
      "content": "![img-15.jpeg](images/bf22317303fa23fc.png)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Hyponatremia Algorithm",
      "line": 1483
    },
    {
      "type": "text",
      "section": "Hyponatremia Algorithm",
      "line": 1485,
      "preview": "Plamsa osmolality ( $\\mathrm{mOsm} / \\mathrm{kg}$ ) $=$ $2 \\times[$ serum Na $]+[$ glucose $] / 18+["
    },
    {
      "type": "table",
      "section": "Hyponatremia Algorithm",
      "line": 1487,
      "preview": "| Step 1: <br> Measure plasma osmolality | Step 2: <br> Measure urine osmolality | Step 3: <br> Dete"
    },
    {
      "type": "table",
      "section": "Hyponatremia Algorithm",
      "line": 1488,
      "preview": "| :--: | :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "Hyponatremia Algorithm",
      "line": 1489,
      "preview": "|  |  |  | History and physical |"
    },
    {
      "type": "table",
      "section": "Hyponatremia Algorithm",
      "line": 1490,
      "preview": "|  | 100 mOsm/kg Inappropriate renal dilution |  | Initial <br> Serum osmolality <br> Urine osmolali"
    },
    {
      "type": "table",
      "section": "Hyponatremia Algorithm",
      "line": 1491,
      "preview": "| $>280 \\mathrm{mOsm} / \\mathrm{kg}$ Isotonic or hypertonic hyponatremia | $>100 \\mathrm{mOsm} / \\ma"
    },
    {
      "type": "table",
      "section": "Hyponatremia Algorithm",
      "line": 1492,
      "preview": "| Hyperglycemia Hypertriglyceridemia Mannitol retention | Hyperglycemia Hypertriglyceridemia Mannito"
    },
    {
      "type": "table",
      "section": "Hyponatremia Algorithm",
      "line": 1493,
      "preview": "| Na correction in hyperglycemia $=$ serum $\\mathrm{Na}+0.016$ (serum glucose - 100) |  | Hypervolem"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Hyponatremia workup",
      "line": 1495
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1497,
      "preview": "History and physical"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1498,
      "preview": "Initial"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1499,
      "preview": "Serum osmolality"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1500,
      "preview": "Urine osmolality"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1501,
      "preview": "Urine Na"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1502,
      "preview": "Urine potassium"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1503,
      "preview": "Additional"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1504,
      "preview": "Extracellular fluid (ECF) status"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1505,
      "preview": "Thyroid stimulating hormone"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1506,
      "preview": "(TSH)"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1507,
      "preview": "Cortisol"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1508,
      "preview": "Uric acid"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1510,
      "preview": "Castillo JJ et al. The Oncologist 2012;17:756-765."
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1511,
      "preview": "Verbalis JG et al. Am J Med. 2013; 126:S1-S42."
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1512,
      "preview": "Kraft MD et al. Am J Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1514,
      "preview": "Castillo JJ et al. The Oncologist 2012;17:756-765."
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1515,
      "preview": "Verbalis JG et al. Am J Med. 2013; 126:S1-S42."
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1516,
      "preview": "Kraft MD et al. Am J Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Hyponatremia workup",
      "line": 1518
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1520,
      "preview": "History and physical"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1521,
      "preview": "Initial"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1522,
      "preview": "Serum osmolality"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1523,
      "preview": "Urine osmolality"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1524,
      "preview": "Urine Na"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1525,
      "preview": "Urine potassium"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1526,
      "preview": "Additional"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1527,
      "preview": "Extracellular fluid (ECF) status"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1528,
      "preview": "Thyroid stimulating hormone"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1529,
      "preview": "(TSH)"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1530,
      "preview": "Cortisol"
    },
    {
      "type": "text",
      "section": "Hyponatremia workup",
      "line": 1531,
      "preview": "Uric acid"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "aspen",
      "line": 1533
    },
    {
      "type": "text",
      "section": "aspen",
      "line": 1535,
      "preview": "LXA8966 THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION"
    },
    {
      "type": "text",
      "section": "aspen",
      "line": 1537,
      "preview": "--- page 22 ---"
    },
    {
      "type": "image",
      "section": "aspen",
      "line": 1539,
      "content": "![img-16.jpeg](images/52d80b5ebc6b3540.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Anti-Diuretic Hormone (ADH)",
      "line": 1541
    },
    {
      "type": "text",
      "section": "Anti-Diuretic Hormone (ADH)",
      "line": 1543,
      "preview": "Arginine vasopressin (AVP)"
    },
    {
      "type": "image",
      "section": "Anti-Diuretic Hormone (ADH)",
      "line": 1544,
      "content": "![img-17.jpeg](images/1074e6d1bcbb75a2.png)"
    },
    {
      "type": "text",
      "section": "Anti-Diuretic Hormone (ADH)",
      "line": 1546,
      "preview": "--- page 23 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "SIADH",
      "line": 1548
    },
    {
      "type": "text",
      "section": "SIADH",
      "line": 1550,
      "preview": "Sustained or intermittently elevated ADH level inappropriate for osmotic and volume status that woul"
    },
    {
      "type": "text",
      "section": "SIADH",
      "line": 1551,
      "preview": "Diagnosis of exclusion"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1553,
      "preview": "| Essential Criteria | Supplemental Criteria |"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1554,
      "preview": "| :-- | :-- |"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1555,
      "preview": "| Effective serum osmolality $<275 \\mathrm{mOsm} / \\mathrm{kg}$ | Serum uric acid $<0.24 \\mathrm{mmo"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1556,
      "preview": "| Urine osmolality $>100 \\mathrm{mOsm} / \\mathrm{kg}$ at some level | Fractional excretion of uric a"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1557,
      "preview": "| of decreased effective osmolality | Serum urea $<3.6 \\mathrm{mmol} / \\mathrm{L}(<21.6 \\mathrm{mg} "
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1558,
      "preview": "| Clinical euvolemia | Fractional excretion of urea $>55 \\%$ |"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1559,
      "preview": "| Urine $\\mathrm{Na}>30 \\mathrm{mmol} / \\mathrm{L}$ (normal dietary sodium | Fractional excretion of"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1560,
      "preview": "| and water intake) | No change in Na level with $0.9 \\%$ sodium |"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1561,
      "preview": "| No adrenal, thyroid, pituitary or renal | chloride $(\\mathrm{NaCl})$ administration |"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1562,
      "preview": "| insufficiency | Na correction with fluid restriction |"
    },
    {
      "type": "table",
      "section": "SIADH",
      "line": 1563,
      "preview": "| No recent diuretic use |  |"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Causes of SIADH",
      "line": 1565
    },
    {
      "type": "text",
      "section": "Causes of SIADH",
      "line": 1567,
      "preview": "Respiratory (small cell lung cancer, pneumonia, abscess, tuberculosis)"
    },
    {
      "type": "text",
      "section": "Causes of SIADH",
      "line": 1568,
      "preview": "Neurologic (tumors, trauma, meningitis, abscess, subarachnoid hemorrhage, pain, anxiety, nausea)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Medications",
      "line": 1570
    },
    {
      "type": "text",
      "section": "Medications",
      "line": 1572,
      "preview": "- Anticancer agents: cyclophosphamide, ifosfamide, vincristine, cisplatin, carboplatin"
    },
    {
      "type": "text",
      "section": "Medications",
      "line": 1573,
      "preview": "- Anticonvulsants: carbamazepine, oxcarbazepine"
    },
    {
      "type": "text",
      "section": "Medications",
      "line": 1574,
      "preview": "- Antidepressants: SSRIs, TCADs, MAOI, venlafaxine"
    },
    {
      "type": "text",
      "section": "Medications",
      "line": 1575,
      "preview": "- Antidiabetic agent: chlorpropamide"
    },
    {
      "type": "text",
      "section": "Medications",
      "line": 1576,
      "preview": "- Antipsychotics: phenothiazines, haloperidol"
    },
    {
      "type": "text",
      "section": "Medications",
      "line": 1577,
      "preview": "- Miscellaneous: opiates, 3,4-methylenedioxy-methamphetamine, NSAIDs"
    },
    {
      "type": "text",
      "section": "Medications",
      "line": 1578,
      "preview": "- Vasopressin analogs: desmopressin, oxytocin, terlipressin, vasopressin"
    },
    {
      "type": "text",
      "section": "Medications",
      "line": 1580,
      "preview": "--- page 24 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hyponatremia Management",
      "line": 1582
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1584,
      "preview": "- Identify and treat underlying cause"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1585,
      "preview": "- Discontinue hypotonic or electrolyte-free fluids"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1586,
      "preview": "- Dextrose 5\\%, 0.45\\% NaCl, free water flushes, extra free water in parenteral nutrition"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1587,
      "preview": "- Replace Na deficit and/or increase Na intake"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1588,
      "preview": "- Change in serum $\\mathrm{Na}=$ infusate $\\mathrm{Na}-$ serum Na"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1590,
      "preview": "TBW +1"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1592,
      "preview": "- Hypertonic saline (3\\%) for severe symptoms"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1593,
      "preview": "- Limit serum Na correction to 8-10 mEq or mmol / Liter per day"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1594,
      "preview": "- Prevention of osmotic demyelination syndrome"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1595,
      "preview": "- Greatest risk: serum $\\mathrm{Na} \\leq 105 \\mathrm{mEq} / \\mathrm{L}$, alcohol abuse, malnutrition"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1597,
      "preview": "Braun MM et al. Am Fam Physician. 2015; 91(5):299-307."
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1598,
      "preview": "Kraft MD et al. Am J Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Hyponatremia Management",
      "line": 1600
    },
    {
      "type": "table",
      "section": "Hyponatremia Management",
      "line": 1602,
      "preview": "| Hyponatremia Type | Treatment (plus treat or remove underlying cause) |"
    },
    {
      "type": "table",
      "section": "Hyponatremia Management",
      "line": 1603,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "Hyponatremia Management",
      "line": 1604,
      "preview": "| Hypertonic | Insulin (hyperglycemia), discontinue mannitol |"
    },
    {
      "type": "table",
      "section": "Hyponatremia Management",
      "line": 1605,
      "preview": "| Hypotonic |  |"
    },
    {
      "type": "table",
      "section": "Hyponatremia Management",
      "line": 1606,
      "preview": "| Hypovolemic | Isotonic fluids ( $0.9 \\% \\mathrm{NaCl}$, lactated ringers), discontinue diuretics, "
    },
    {
      "type": "table",
      "section": "Hyponatremia Management",
      "line": 1607,
      "preview": "| Euvolemic | Fluid restriction $\\pm$ loop diuretics, concentrate PN, ensure at least isotonic fluid"
    },
    {
      "type": "table",
      "section": "Hyponatremia Management",
      "line": 1608,
      "preview": "| Hypervolemic | Na and fluid restriction, concentrate PN, diuretics, vaptans |"
    },
    {
      "type": "text",
      "section": "Hyponatremia Management",
      "line": 1610,
      "preview": "--- page 25 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypernatremia",
      "line": 1612
    },
    {
      "type": "text",
      "section": "Hypernatremia",
      "line": 1614,
      "preview": "- Too much sodium relative to water"
    },
    {
      "type": "text",
      "section": "Hypernatremia",
      "line": 1615,
      "preview": "- All cases reflect hypertonic state"
    },
    {
      "type": "text",
      "section": "Hypernatremia",
      "line": 1616,
      "preview": "- Types divided by ECF volume status"
    },
    {
      "type": "table",
      "section": "Hypernatremia",
      "line": 1618,
      "preview": "|  Hypernatremia | Na / Water Balance | Common Causes  |"
    },
    {
      "type": "table",
      "section": "Hypernatremia",
      "line": 1619,
      "preview": "| --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Hypernatremia",
      "line": 1620,
      "preview": "|  Hypovolemic | \u2193 Na / \u2193\u2193 water | Osmotic or solute diuresis, post-obstructive diuresis, vomiting, "
    },
    {
      "type": "table",
      "section": "Hypernatremia",
      "line": 1621,
      "preview": "|  Euvolemic | nL Na / \u2193 water | Central diabetes insipidus, nephrogenic DI (hypercalcemia, hypokale"
    },
    {
      "type": "table",
      "section": "Hypernatremia",
      "line": 1622,
      "preview": "|  Hypervolemic | \u2191\u2191 Na / \u2191 water | Hypertonic saline or Na bicarbonate infusions, hyperaldosteronis"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypernatremia Management",
      "line": 1624
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1626,
      "preview": "- Identify and treat underlying cause"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1627,
      "preview": "- Discontinue hypertonic fluids"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1628,
      "preview": "- Correct water deficit"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1629,
      "preview": "- Water deficit (L) = TBW x [(serum Na \u2212 140)/140]"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1630,
      "preview": "- TBW = 0.6 x weight (males) or 0.5 x weight (females)"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1631,
      "preview": "- Administer 50% within first 24 hours, remainder over next 24-48 hours"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1632,
      "preview": "- Isotonic fluids (0.9% NaCl, lactated ringers) for hemodynamic instability"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1633,
      "preview": "- Switch to hypotonic fluids / free water when stable"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1634,
      "preview": "- Limit serum Na correction to 8-10 mEq or mmol / Liter per day"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1635,
      "preview": "- Prevention of cerebral edema"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1637,
      "preview": "Braun MM et al. Am Fam Physician. 2015; 91(5):299-307. Kraft MD et al. Am J Health-Syst Pharm. 2005;"
    },
    {
      "type": "text",
      "section": "Hypernatremia Management",
      "line": 1639,
      "preview": "--- page 26 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1641
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1643,
      "preview": "- Water deficit (L) $=$ TBW $\\times[($ serum $\\mathrm{Na}-140) / 140]$"
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1644,
      "preview": "$=70 \\times 0.6[(160-140) / 140]$"
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1645,
      "preview": "$=42[20 / 140]$"
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1646,
      "preview": "$=6$ Liters"
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1647,
      "preview": "- TBW $=0.6 \\times$ wt (males)"
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1648,
      "preview": "- Administer 50\\% within first 24 hours, remainder over next 24-48 hours"
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1649,
      "preview": "- Can give as free water oral/enterally or hypotonic fluid intravenously (5\\% dextrose, $0.2 \\% \\mat"
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1651,
      "preview": "Hypernatremia Management"
    },
    {
      "type": "table",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1653,
      "preview": "| Hypernatremia Type | Treatment (plus treat or remove underlying cause) |"
    },
    {
      "type": "table",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1654,
      "preview": "| :--: | :--: |"
    },
    {
      "type": "table",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1655,
      "preview": "| Hypovolemic | Replace free water deficit (oral water, enteral water flushes, dextrose 5\\% in water"
    },
    {
      "type": "table",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1656,
      "preview": "| Euvolemic | Desmopressin (central diabetes insipidus) <br> Remove offending agent, potassium repla"
    },
    {
      "type": "table",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1657,
      "preview": "| Hypervolemic | Loop diuretic, hypotonic fluids (Na overload), spironolactone/adrenalectomy (hypera"
    },
    {
      "type": "text",
      "section": "Calculation of Water Deficit 70 kg male with a serum Na of 160mEq/L",
      "line": 1659,
      "preview": "--- page 27 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Self-assessment Question \\#2",
      "line": 1661
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#2",
      "line": 1663,
      "preview": "A patient presents with hypotonic hyponatremia and is currently on sertraline. What subtype of hypon"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#2",
      "line": 1664,
      "preview": "A. Hypovolemic"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#2",
      "line": 1665,
      "preview": "B. Euvolemic"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#2",
      "line": 1666,
      "preview": "C. Hypervolemic"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#2",
      "line": 1667,
      "preview": "D. None of the above"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Self-assessment Question \\#3",
      "line": 1669
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#3",
      "line": 1671,
      "preview": "Which of the following sodium concentrations ( $\\mathrm{mEq} / \\mathrm{L}$ ) is the most appropriate"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#3",
      "line": 1672,
      "preview": "A. 38.5 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#3",
      "line": 1673,
      "preview": "B. 77 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#3",
      "line": 1674,
      "preview": "C. 115 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#3",
      "line": 1675,
      "preview": "D. 154 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#3",
      "line": 1677,
      "preview": "--- page 28 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Potassium (K)",
      "line": 1679
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1681,
      "preview": "- Normal serum potassium (K) $3.5-5 \\mathrm{mEq}$ or mEq / Liter"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1682,
      "preview": "- Most abundant intracellular cation"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1683,
      "preview": "- Normal intracellular concentration $140-150 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1684,
      "preview": "- Functions in maintaining resting membrane potential, metabolism, protein and glycogen synthesis"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1685,
      "preview": "- Na-K-ATPase pump regulates entry of K into the cell"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1686,
      "preview": "- Intracellular shift: insulin, catecholamines, alkalosis"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1687,
      "preview": "- Extracellular shift: glucagon, acidosis, aldosterone (allows renal elimination)"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1688,
      "preview": "- Kidneys can decrease K excretion to no lower than $10 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1690,
      "preview": "Intracellular Buffering of Potassium"
    },
    {
      "type": "image",
      "section": "Potassium (K)",
      "line": 1691,
      "content": "![img-18.jpeg](images/b476bece66bba6db.png)"
    },
    {
      "type": "text",
      "section": "Potassium (K)",
      "line": 1693,
      "preview": "--- page 29 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypokalemia",
      "line": 1695
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1697,
      "preview": "- Serum potassium $<3.5 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1698,
      "preview": "- Signs / symptoms"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1699,
      "preview": "- Muscle weakness, cramps"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1700,
      "preview": "- Easy fatigability"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1701,
      "preview": "- lleus"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1702,
      "preview": "- ECG changes"
    },
    {
      "type": "image",
      "section": "Hypokalemia",
      "line": 1703,
      "content": "![img-19.jpeg](images/18a0b6ff1c902f9c.png)"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1705,
      "preview": "Etiology of Hypokalemia"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1707,
      "preview": "- Kidney losses- diuretics, hyperaldosteronism, amphotericin, aminoglycosides"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1708,
      "preview": "- Gl tract losses"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1709,
      "preview": "- Diarrhea ( $10 \\mathrm{mEq} / \\mathrm{L}$ )"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1710,
      "preview": "- Emesis / NG losses (up to $50 \\mathrm{mEq} / \\mathrm{L}$ )"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1711,
      "preview": "- Skin losses - burns, strenuous exercise on hot humid day"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1712,
      "preview": "- Altered distribution - alkalosis, catecholamine surge, excessive insulin"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1713,
      "preview": "- Dietary - inadequate intake, large volumes of IV saline, pica"
    },
    {
      "type": "text",
      "section": "Hypokalemia",
      "line": 1715,
      "preview": "--- page 30 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypokalemia Management",
      "line": 1717
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1719,
      "preview": "- Dietary modification, salt substitutes"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1720,
      "preview": "- Replacing hypomagnesemia first may help with hypokalemia correction"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1721,
      "preview": "- Oral potassium therapy"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1722,
      "preview": "- Asymptomatic, able to take oral medications"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1723,
      "preview": "- Gastrointestinal adverse effect - large doses should be divided"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1724,
      "preview": "- Liquid preparations may cause diarrhea"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1725,
      "preview": "- Parenteral potassium therapy"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1726,
      "preview": "- Symptomatic, malabsorptive conditions, unable to take oral medications"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1727,
      "preview": "- Adverse effects - phlebitis, hyperkalemia, arrhythmias"
    },
    {
      "type": "text",
      "section": "Hypokalemia Management",
      "line": 1728,
      "preview": "- Potassium-sparing diuretics"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Parenteral Potassium",
      "line": 1731
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1733,
      "preview": "- Empiric potassium dose in PN: 1-2 mEq/kg/day"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1734,
      "preview": "- 10 mEq of K intravenously increases serum K by $\\sim 0.1 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1735,
      "preview": "- Assumes normal renal and gastrointestinal function"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1736,
      "preview": "- Decrease dose by $50 \\%$ in renal impairment"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1737,
      "preview": "- Dilution"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1738,
      "preview": "- Sodium chloride-containing solutions"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1739,
      "preview": "- Peripheral IV infusion: dilute 10 mEq potassium / 100 mL maximum"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1740,
      "preview": "- Central IV infusion: can give more concentrated; check institutional policy"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1741,
      "preview": "- Infusion rates"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1742,
      "preview": "- $\\leq 10 \\mathrm{mEq} / \\mathrm{hr}$ : no cardiac monitoring / peripheral IV access"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1743,
      "preview": "- $>10 \\mathrm{mEq} / \\mathrm{hr}$ : cardiac monitoring / central IV access"
    },
    {
      "type": "text",
      "section": "Parenteral Potassium",
      "line": 1745,
      "preview": "--- page 31 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hyperkalemia",
      "line": 1747
    },
    {
      "type": "text",
      "section": "Hyperkalemia",
      "line": 1749,
      "preview": "- Serum potassium $>5 \\mathrm{mEq} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Hyperkalemia",
      "line": 1750,
      "preview": "- Signs / symptoms"
    },
    {
      "type": "text",
      "section": "Hyperkalemia",
      "line": 1751,
      "preview": "- Muscle weakness, paralysis"
    },
    {
      "type": "text",
      "section": "Hyperkalemia",
      "line": 1752,
      "preview": "- ECG changes"
    },
    {
      "type": "text",
      "section": "Hyperkalemia",
      "line": 1753,
      "preview": "- Arrythmias"
    },
    {
      "type": "image",
      "section": "Hyperkalemia",
      "line": 1754,
      "content": "![img-20.jpeg](images/9e011459697452d8.png)"
    },
    {
      "type": "text",
      "section": "Hyperkalemia",
      "line": 1756,
      "preview": "49"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Etiology of Hyperkalemia",
      "line": 1758
    },
    {
      "type": "text",
      "section": "Etiology of Hyperkalemia",
      "line": 1760,
      "preview": "- Traumatic blood draw - hemolyzed specimen"
    },
    {
      "type": "text",
      "section": "Etiology of Hyperkalemia",
      "line": 1761,
      "preview": "- Excessive intake - usually IV administration"
    },
    {
      "type": "text",
      "section": "Etiology of Hyperkalemia",
      "line": 1762,
      "preview": "- Altered distribution - acidosis, succinylcholine"
    },
    {
      "type": "text",
      "section": "Etiology of Hyperkalemia",
      "line": 1763,
      "preview": "- Massive cellular breakdown - intravascular hemolysis, burns, crush injuries, tumor lysis syndrome"
    },
    {
      "type": "text",
      "section": "Etiology of Hyperkalemia",
      "line": 1764,
      "preview": "- Impaired renal excretion"
    },
    {
      "type": "text",
      "section": "Etiology of Hyperkalemia",
      "line": 1765,
      "preview": "- Acute kidney injury (AKI), chronic kidney disease (CKD) 4/5"
    },
    {
      "type": "text",
      "section": "Etiology of Hyperkalemia",
      "line": 1766,
      "preview": "- ACEI, ARBs, K-sparing diuretics, aldosterone antagonists, NSAIDs, trimethoprim, tacrolimus"
    },
    {
      "type": "text",
      "section": "Etiology of Hyperkalemia",
      "line": 1768,
      "preview": "--- page 32 ---"
    },
    {
      "type": "heading",
      "level": 3,
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1770
    },
    {
      "type": "text",
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1772,
      "preview": "- Stabilize myocardium"
    },
    {
      "type": "text",
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1773,
      "preview": "- Shift potassium intracellularly"
    },
    {
      "type": "text",
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1774,
      "preview": "- Remove potassium"
    },
    {
      "type": "image",
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1776,
      "content": "![img-21.jpeg](images/2269a2d314a5ea85.png)"
    },
    {
      "type": "text",
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1778,
      "preview": "- 1-2 minutes"
    },
    {
      "type": "text",
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1779,
      "preview": "- 30 minutes"
    },
    {
      "type": "text",
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1780,
      "preview": "- 60 + minutes"
    },
    {
      "type": "image",
      "section": "**\"K Cocktail\" K > 6 mEq/L or ECG changes**",
      "line": 1782,
      "content": "![img-22.jpeg](images/5e5201571c1db753.png)"
    },
    {
      "type": "heading",
      "level": 3,
      "section": "**Hyperkalemia Management**",
      "line": 1784
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1786,
      "preview": "|  Agent | Dose / Route | Onset / Duration  |"
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1787,
      "preview": "| --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1788,
      "preview": "|  **Myocardial stabilization** |  |   |"
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1789,
      "preview": "|  Calcium gluconate | 1-2 grams IV | 1-2 min / 10-30 min  |"
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1790,
      "preview": "|  **Cellular incorporation (ECF to ICF shift)** |  |   |"
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1791,
      "preview": "|  Regular insulin + Dextrose 50% | 10 units IV"
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1792,
      "preview": "25 gram IV | 15-45 min / 2-6 hours  |"
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1793,
      "preview": "|  Sodium bicarbonate | 50-100 mEq IV | 30 min / 2-6 hours  |"
    },
    {
      "type": "table",
      "section": "**Hyperkalemia Management**",
      "line": 1794,
      "preview": "|  Albuterol | 10-20 mg nebulized | 30 min / 1-2 hours  |"
    },
    {
      "type": "image",
      "section": "**Hyperkalemia Management**",
      "line": 1796,
      "content": "![img-23.jpeg](images/2f994797170788f1.png)"
    },
    {
      "type": "text",
      "section": "**Hyperkalemia Management**",
      "line": 1798,
      "preview": "--- page 33 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hyperkalemia Management",
      "line": 1800
    },
    {
      "type": "table",
      "section": "Hyperkalemia Management",
      "line": 1802,
      "preview": "|  Agent | Dose / Route | Onset / Duration  |"
    },
    {
      "type": "table",
      "section": "Hyperkalemia Management",
      "line": 1803,
      "preview": "| --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Hyperkalemia Management",
      "line": 1804,
      "preview": "|  **Increase potassium elimination** |  |   |"
    },
    {
      "type": "table",
      "section": "Hyperkalemia Management",
      "line": 1805,
      "preview": "|  Furosemide | 20-40 mg IV | 5-15 min / 4-6 hours  |"
    },
    {
      "type": "table",
      "section": "Hyperkalemia Management",
      "line": 1806,
      "preview": "|  Sodium polystyrene sulfonate | 15-60 grams PO or PR | 60 min / 4-6 hours  |"
    },
    {
      "type": "table",
      "section": "Hyperkalemia Management",
      "line": 1807,
      "preview": "|  Patiromer (not for acute use) | 8.4 grams PO daily | 7 hours / 24 hours  |"
    },
    {
      "type": "table",
      "section": "Hyperkalemia Management",
      "line": 1808,
      "preview": "|  Sodium zirconium cyclosilicate | 10 grams PO 3 times daily x 48 hours, then 10 grams PO daily | 1"
    },
    {
      "type": "table",
      "section": "Hyperkalemia Management",
      "line": 1809,
      "preview": "|  Hemodialysis | 2-4 hours | Immediate / Variable  |"
    },
    {
      "type": "image",
      "section": "Hyperkalemia Management",
      "line": 1811,
      "content": "![img-24.jpeg](images/84672cfb8e907e7a.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Self-assessment Question #4",
      "line": 1813
    },
    {
      "type": "text",
      "section": "Self-assessment Question #4",
      "line": 1815,
      "preview": "Which of the following is/are important considerations when ordering parenteral potassium supplement"
    },
    {
      "type": "text",
      "section": "Self-assessment Question #4",
      "line": 1817,
      "preview": "- A. Location of patient"
    },
    {
      "type": "text",
      "section": "Self-assessment Question #4",
      "line": 1818,
      "preview": "- B. Type of intravenous access"
    },
    {
      "type": "text",
      "section": "Self-assessment Question #4",
      "line": 1819,
      "preview": "- C. Renal function"
    },
    {
      "type": "text",
      "section": "Self-assessment Question #4",
      "line": 1820,
      "preview": "- D. All of the above"
    },
    {
      "type": "text",
      "section": "Self-assessment Question #4",
      "line": 1822,
      "preview": "--- page 34 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Self-assessment Question \\#5",
      "line": 1824
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#5",
      "line": 1826,
      "preview": "A patient presents with peaked T-waves on ECG and a serum potassium of $6.5 \\mathrm{mEq} / \\mathrm{L"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#5",
      "line": 1827,
      "preview": "A. Furosemide"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#5",
      "line": 1828,
      "preview": "B. Calcium gluconate"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#5",
      "line": 1829,
      "preview": "C. Albuterol"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#5",
      "line": 1830,
      "preview": "D. Insulin"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Magnesium",
      "line": 1832
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1834,
      "preview": "- Second most abundant intracellular cation"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1835,
      "preview": "- $50 \\%$ in bone and $50 \\%$ in soft tissue"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1836,
      "preview": "- Normal serum magnesium $1.7-2.4 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1837,
      "preview": "- Absorbed in the jejunum and regulated by the kidney"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1838,
      "preview": "- Important as enzyme cofactor, nature's calcium blocker, neuromuscular transmission and cardiovascu"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1839,
      "preview": "- Maintaining high-normal range serum $\\mathrm{Mg} \\sim 2.7 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1840,
      "preview": "- Reduces ventricular ectopy"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1841,
      "preview": "- Improves $\\mathrm{K}^{+}$retention"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1842,
      "preview": "- Hypermagnesemia not common, typically associated with renal dysfunction"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1843,
      "preview": "- Treatment reduced intake, increased excretion, supportive care measures"
    },
    {
      "type": "text",
      "section": "Magnesium",
      "line": 1845,
      "preview": "--- page 35 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Etiology of Hypomagnesemia",
      "line": 1847
    },
    {
      "type": "text",
      "section": "Etiology of Hypomagnesemia",
      "line": 1849,
      "preview": "- Poor intake"
    },
    {
      "type": "text",
      "section": "Etiology of Hypomagnesemia",
      "line": 1850,
      "preview": "- Malabsorption / gastrointestinal loss"
    },
    {
      "type": "text",
      "section": "Etiology of Hypomagnesemia",
      "line": 1851,
      "preview": "- Small bowel diseases, gastric bypass, alcoholism, laxatives, diarrhea"
    },
    {
      "type": "text",
      "section": "Etiology of Hypomagnesemia",
      "line": 1852,
      "preview": "- Intracellular shift (insulin)"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Hypomagnesemia and Proton Pump Inhibitors",
      "line": 1855
    },
    {
      "type": "text",
      "section": "Hypomagnesemia and Proton Pump Inhibitors",
      "line": 1857,
      "preview": "- Long term PPI use may be associated with hypomagnesemia"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia and Proton Pump Inhibitors",
      "line": 1858,
      "preview": "- Hypomagnesemia may persist despite Mg supplements"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia and Proton Pump Inhibitors",
      "line": 1859,
      "preview": "- Mg levels returned to normal after stopping PPI's"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia and Proton Pump Inhibitors",
      "line": 1860,
      "preview": "- Histamine-2 receptor blockers (e.g., famotidine) without effect"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia and Proton Pump Inhibitors",
      "line": 1862,
      "preview": "--- page 36 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypomagnesemia Management",
      "line": 1864
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1866,
      "preview": "- Dietary modification"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1867,
      "preview": "- Oral magnesium therapy"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1868,
      "preview": "- Asymptomatic, able to take oral medications"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1869,
      "preview": "- Magnesium oxide and magnesium hydroxide"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1870,
      "preview": "- Adverse effect - abdominal cramping, diarrhea"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1871,
      "preview": "- May be difficult to replace magnesium deficits orally if large doses for multiple days are require"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1872,
      "preview": "- Parenteral magnesium therapy"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1873,
      "preview": "- Symptomatic, malabsorptive conditions, unable to take oral medications"
    },
    {
      "type": "text",
      "section": "Hypomagnesemia Management",
      "line": 1874,
      "preview": "- Adverse effects - phlebitis, injection site pain"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Parenteral Magnesium",
      "line": 1877
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1879,
      "preview": "- Decrease dose by $50 \\%$ in renal impairment"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1880,
      "preview": "- Empiric magnesium dose in PN: 0.3-0.5 mEq/kg/day"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1881,
      "preview": "- 8 mEq of Mg intravenously increases serum Mg by $\\sim 0.1 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1882,
      "preview": "- Assumes normal renal and gastrointestinal function"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1883,
      "preview": "- Dosing"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1884,
      "preview": "- Serum Mg 1-1.5 mg/dL: 8-32 mEq, up to $1 \\mathrm{mEq} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1885,
      "preview": "- Serum $\\mathrm{Mg}<1 \\mathrm{mg} / \\mathrm{dL}$ : 32-64 mEq, up to $1.5 \\mathrm{mEq} / \\mathrm{kg}"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1886,
      "preview": "- Infusion rates"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1887,
      "preview": "- $\\leq 8 \\mathrm{mEq} \\mathrm{Mg}$ per hour"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1888,
      "preview": "- Prevents renal wasting and infusion reactions"
    },
    {
      "type": "text",
      "section": "Parenteral Magnesium",
      "line": 1890,
      "preview": "--- page 37 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Self-assessment Question \\#6",
      "line": 1892
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#6",
      "line": 1894,
      "preview": "A patient is noted to have a serum magnesium of $1.5 \\mathrm{mg} / \\mathrm{dL}$. Serum creatinine is"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#6",
      "line": 1895,
      "preview": "a. Magnesium supplementation is not indicated"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#6",
      "line": 1896,
      "preview": "b. 16 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#6",
      "line": 1897,
      "preview": "c. 24 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "Self-assessment Question \\#6",
      "line": 1898,
      "preview": "d. 48 mEq magnesium sulfate"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Calcium",
      "line": 1900
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1902,
      "preview": "- Majority of calcium stored in bones and teeth"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1903,
      "preview": "- $1 \\%$ is extracellular and $60 \\%$ of that is bound to albumin"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1904,
      "preview": "- Normal serum calcium 9-10.5 mg/dL"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1905,
      "preview": "- Normal serum ionized serum calcium"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1906,
      "preview": "- $4.4-5.4 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1907,
      "preview": "- $1.1-1.35 \\mathrm{mmol} / \\mathrm{L}$"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1908,
      "preview": "- Albumin-corrected $\\mathrm{Ca}^{2+}$ equation (not reliable in critically ill)"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1909,
      "preview": "- Corrected $\\mathrm{Ca}^{2+}=0.8$ (4 - measured albumin) + measured $\\mathrm{Ca}^{2+}$"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1910,
      "preview": "- Essential for normal muscle contraction, nerve function, blood coagulation and bone formation"
    },
    {
      "type": "text",
      "section": "Calcium",
      "line": 1912,
      "preview": "--- page 38 ---"
    },
    {
      "type": "image",
      "section": "Calcium",
      "line": 1914,
      "content": "![img-25.jpeg](images/03371fb46155b7e0.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypocalcemia Management",
      "line": 1916
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1918,
      "preview": "- Correct hypomagnesemia if present (reduced parathyroid hormone)"
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1919,
      "preview": "- Oral calcium therapy"
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1920,
      "preview": "- Asymptomatic, able to take oral medications"
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1921,
      "preview": "- Elemental calcium content or oral products varies by salt (9-40\\%)"
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1922,
      "preview": "- Adverse effect - constipation"
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1923,
      "preview": "- Oral vitamin D therapy"
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1924,
      "preview": "- Parenteral calcium therapy"
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1925,
      "preview": "- Symptomatic, malabsorptive conditions, unable to take oral medications"
    },
    {
      "type": "text",
      "section": "Hypocalcemia Management",
      "line": 1927,
      "preview": "--- page 39 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Oral Calcium Supplements",
      "line": 1929
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1931,
      "preview": "|  Calcium Salt | Elemental Ca"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1932,
      "preview": "(mEq/g) | Elemental"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1933,
      "preview": "Ca % | Formulation | Admin"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1934,
      "preview": "Route  |"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1935,
      "preview": "| --- | --- | --- | --- | --- |"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1936,
      "preview": "|  Calcium chloride | 13.6 | 27 | 1 g / 10 ml | IV  |"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1937,
      "preview": "|  Calcium gluconate | 4.56 | 9 | 1 g / 10 ml"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1938,
      "preview": "500 mg tab | IV or PO  |"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1939,
      "preview": "|  Calcium acetate | 12.7 | 25 | 667 mg tab | PO  |"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1940,
      "preview": "|  Calcium carbonate | 20 | 40 | 500 mg tab | PO  |"
    },
    {
      "type": "table",
      "section": "Oral Calcium Supplements",
      "line": 1941,
      "preview": "|  Calcium citrate | 10.5 | 21 | 950 mg tab | PO  |"
    },
    {
      "type": "image",
      "section": "Oral Calcium Supplements",
      "line": 1943,
      "content": "![img-26.jpeg](images/84672cfb8e907e7a.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral Calcium",
      "line": 1945
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1947,
      "preview": "- **Empiric calcium dose in PN: 10-15 mEq/day**"
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1948,
      "preview": "- Always check calcium-phosphate compatibility"
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1949,
      "preview": "- Calcium may be removed from PN for short periods in adults"
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1950,
      "preview": "- **Gluconate salt preferred in PN and peripheral IV**"
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1951,
      "preview": "- 1 g calcium gluconate = 4.65 mEq elemental calcium"
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1952,
      "preview": "- 1 g calcium chloride = 13.6 mEq elemental calcium"
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1953,
      "preview": "- Bolus dosing versus continuous infusions"
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1954,
      "preview": "- Adverse effects: infusion-related, hypotension, bradycardia"
    },
    {
      "type": "text",
      "section": "Parenteral Calcium",
      "line": 1956,
      "preview": "--- page 40 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Hypercalcemia",
      "line": 1958
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1960,
      "preview": "- Acute > hypercalcemia of malignancy"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1961,
      "preview": "- Chronic > primary hyperparathyroidism"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1962,
      "preview": "- Treatment"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1963,
      "preview": "- Treat underlying cause"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1964,
      "preview": "- Hydration $\\pm$ loop diuretics"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1965,
      "preview": "- Calcitonin (rapid onset, tachyphylaxis)"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1966,
      "preview": "- Bisphosphonates (slower onset, longer duration)"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1967,
      "preview": "- Steroids"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1968,
      "preview": "- Surgery (primary hyperparathyroidism)"
    },
    {
      "type": "text",
      "section": "Hypercalcemia",
      "line": 1970,
      "preview": "Kraft MD et al. Am J Health-Syst Pharm. 2005; 62:1663-82."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Phosphorous",
      "line": 1972
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1974,
      "preview": "- Primary intracellular anion"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1975,
      "preview": "- Major component of bone and teeth"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1976,
      "preview": "- Normal serum phosphorus $2.5-4.5 \\mathrm{mg} / \\mathrm{dL}$"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1977,
      "preview": "- Essential part of nucleic acids, phospholipid membranes and nucleoproteins. Key role in macronutri"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1978,
      "preview": "- Hormonal regulation"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1979,
      "preview": "- Vitamin D"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1980,
      "preview": "- Parathyroid hormone"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1981,
      "preview": "- Calcitonin"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1982,
      "preview": "- Hyperphosphatemia rare, typically associated with renal dysfunction"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1983,
      "preview": "- Treatment reduced intake, phosphate binders"
    },
    {
      "type": "text",
      "section": "Phosphorous",
      "line": 1985,
      "preview": "--- page 41 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Etiology of Hypophosphatemia",
      "line": 1987
    },
    {
      "type": "text",
      "section": "Etiology of Hypophosphatemia",
      "line": 1989,
      "preview": "- Poor intake"
    },
    {
      "type": "text",
      "section": "Etiology of Hypophosphatemia",
      "line": 1990,
      "preview": "- Poor absorption"
    },
    {
      "type": "text",
      "section": "Etiology of Hypophosphatemia",
      "line": 1991,
      "preview": "- Phosphate binders, vitamin D deficiency, laxatives, diarrhea"
    },
    {
      "type": "text",
      "section": "Etiology of Hypophosphatemia",
      "line": 1992,
      "preview": "- Increased renal excretion"
    },
    {
      "type": "text",
      "section": "Etiology of Hypophosphatemia",
      "line": 1993,
      "preview": "- Hyperparathyroidism, burns"
    },
    {
      "type": "text",
      "section": "Etiology of Hypophosphatemia",
      "line": 1994,
      "preview": "- Diuretics, corticosteroids, foscarnet"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Hypophosphatemia Management",
      "line": 1997
    },
    {
      "type": "text",
      "section": "Hypophosphatemia Management",
      "line": 1999,
      "preview": "- Oral phosphate therapy"
    },
    {
      "type": "text",
      "section": "Hypophosphatemia Management",
      "line": 2000,
      "preview": "- Asymptomatic, able to take oral medications"
    },
    {
      "type": "text",
      "section": "Hypophosphatemia Management",
      "line": 2001,
      "preview": "- Neutraphos, KPhos neutral, sodium phosphate liquid"
    },
    {
      "type": "text",
      "section": "Hypophosphatemia Management",
      "line": 2002,
      "preview": "- Adverse effect - abdominal cramping, osmotic diarrhea"
    },
    {
      "type": "text",
      "section": "Hypophosphatemia Management",
      "line": 2003,
      "preview": "- Parenteral phosphate therapy"
    },
    {
      "type": "text",
      "section": "Hypophosphatemia Management",
      "line": 2004,
      "preview": "- Symptomatic, malabsorptive conditions, unable to take oral medications"
    },
    {
      "type": "text",
      "section": "Hypophosphatemia Management",
      "line": 2006,
      "preview": "--- page 42 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Parenteral Phosphate",
      "line": 2008
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2010,
      "preview": "- Decrease dose by $50 \\%$ in renal impairment"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2011,
      "preview": "- Empiric phosphate dose in PN: 0.3-0.5 mmol/kg/day"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2012,
      "preview": "- Check Na and K to determine appropriate phosphate salt"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2013,
      "preview": "- $1 \\mathrm{mmol} \\mathrm{K}_{3} \\mathrm{PO}_{4}=1.5 \\mathrm{mEq} \\mathrm{K}$"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2014,
      "preview": "- $1 \\mathrm{mmol} \\mathrm{NaPO}_{4}=1.33 \\mathrm{mEq} \\mathrm{Na}$"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2015,
      "preview": "- Phosphorus replacement dosing"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2016,
      "preview": "- Serum P 2.3-2.7 mg/dL: 0.08-0.16 mmol/kg"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2017,
      "preview": "- Serum P 1.5-2.2 mg/dL: 0.16-0.32 mmol/kg"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2018,
      "preview": "- Serum $\\mathrm{P}<1.5 \\mathrm{mg} / \\mathrm{dL}: 0.32-0.64 \\mathrm{mmol} / \\mathrm{kg}$"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2019,
      "preview": "- Infusion rate $\\leq 7$ mmol phosphate per hour"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2021,
      "preview": "LIAISING THE SCIENCE AND"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2022,
      "preview": "PRACTICE OF CLINICAL NUTRITION"
    },
    {
      "type": "text",
      "section": "Parenteral Phosphate",
      "line": 2023,
      "preview": "American Society for Parenteral and Enteral Nutrition"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2025
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2027,
      "preview": "Sodium Phosphate ( $\\mathrm{NaPhos} / \\mathrm{NaPO}_{4}$ )"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2028,
      "preview": "$1 \\mathrm{mmol} \\mathrm{NaPO}_{4}=1.33 \\mathrm{mEq} \\mathrm{Na}^{+}$"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2029,
      "preview": "$30 \\mathrm{mmol} \\mathrm{NaPO}_{4}=30 \\times 1.33=\\sim 40 \\mathrm{mEq} \\mathrm{Na}^{+}$"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2031,
      "preview": "Consideration in sodium-sensitive disease states / conditions"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2033,
      "preview": "- Heart failure"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2034,
      "preview": "- Ascites"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2035,
      "preview": "- Renal failure"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2036,
      "preview": "- Nephrotic syndrome"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2037,
      "preview": "- Anasarca"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2038,
      "preview": "- Elevated or near elevated serum sodium levels"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2040,
      "preview": "Potassium Phosphate ( $\\mathrm{KPhos} / \\mathrm{K}_{3} \\mathrm{PO}_{4}$ )"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2041,
      "preview": "$1 \\mathrm{mmol} \\mathrm{K}_{3} \\mathrm{PO}_{4}=1.5 \\mathrm{mEq} \\mathrm{K}^{+}$"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2042,
      "preview": "$30 \\mathrm{mmol} \\mathrm{K}_{3} \\mathrm{PO}_{4}=30 \\times 1.5=\\sim 45 \\mathrm{mEq} \\mathrm{K}^{+}$"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2044,
      "preview": "Consideration in potassium-sensitive disease states / conditions"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2046,
      "preview": "- Acute kidney injury"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2047,
      "preview": "- Chronic kidney disease"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2048,
      "preview": "- Patients on potassium-retaining medications"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2049,
      "preview": "- Elevated or near elevated serum potassium levels"
    },
    {
      "type": "text",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2051,
      "preview": "--- page 43 ---"
    },
    {
      "type": "image",
      "section": "Calculating Na and K in Phosphate Supplementation",
      "line": 2053,
      "content": "![img-27.jpeg](images/8fb945ac18f273e9.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2055
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2057,
      "preview": "Table 3. ASPEN Consensus Criteria for Identifying Adult Patients at Risk for Refeeding Syndrome. ${ "
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2059,
      "preview": "|  | Moderate Risk: 2 Risk Criteria Needed | Significant Risk: 1 Risk Criteria Needed |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2060,
      "preview": "| :--: | :--: | :--: |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2061,
      "preview": "| BMI | $16-18.5 \\mathrm{~kg} / \\mathrm{m}^{2}$ | $<16 \\mathrm{~kg} / \\mathrm{m}^{2}$ |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2062,
      "preview": "| Weight loss | $5 \\%$ in 1 month | $7.5 \\%$ in 3 months or $>10 \\%$ in 6 months |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2063,
      "preview": "| Caloric intake | None or negligible oral intake for 5-6 days OR $<75 \\%$ of estimated energy requi"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2064,
      "preview": "| Abnormal prefeeding potassium, phosphorus, or magnesium serum concentrations ${ }^{a}$ | Minimally"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2065,
      "preview": "| Loss of subcutaneous fat | Evidence of moderate loss | Evidence of severe loss |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2066,
      "preview": "| Loss of muscle mass | Evidence of mild or moderate loss | Evidence of severe loss |"
    },
    {
      "type": "table",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2067,
      "preview": "| Higher-risk comorbidities (see Table 4) | Moderate disease | Severe disease |"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2069,
      "preview": "[^0]"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2070,
      "preview": "[^0]:    ASPEN, American Society for Parenteral and Enteral Nutrition; BMI, body mass index."
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2071,
      "preview": "${ }^{a}$ Please note that electrolytes may be normal despite total-body deficiency, which is believ"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome",
      "line": 2073,
      "preview": "--- page 44 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2075
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2077,
      "preview": "- Check serum K, Mg, and Phos before initiation of nutrition"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2078,
      "preview": "- Correct severe deficiencies of $\\mathrm{P}, \\mathrm{K}$ and Mg before providing nutrition"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2079,
      "preview": "- Start with 100-150 g of dextrose or 10-20 kcal/kg"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2080,
      "preview": "- Include dextrose from other sources (IV fluids, IVPB, etc)"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2081,
      "preview": "- Advance by $33 \\%$ per day over 1-2 days"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2082,
      "preview": "- If electrolytes difficult to correct or drop precipitously during initiation of nutrition, decreas"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2083,
      "preview": "- No recommendations for fluid, Na or protein restriction"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2084,
      "preview": "- Thiamine $100 \\mathrm{mg} / \\mathrm{d}$ for 5-7 days or longer"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2085,
      "preview": "- MVI daily"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2086,
      "preview": "aspen"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2087,
      "preview": "LEASING THE SCIENCE AND"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2088,
      "preview": "PRACTICE OF SURVEAL NUTRITION"
    },
    {
      "type": "text",
      "section": "ASPEN Consensus Recommendations for Refeeding Syndrome - Management",
      "line": 2089,
      "preview": "Associate Society for Parenteral and Enteral Nutrition"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Learning Assessment Answers",
      "line": 2092
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers",
      "line": 2094,
      "preview": "1. Answer $=\\mathrm{D}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers",
      "line": 2095,
      "preview": "2. Answer $=\\mathrm{B}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers",
      "line": 2096,
      "preview": "3. Answer $=\\mathrm{D}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers",
      "line": 2097,
      "preview": "4. Answer $=\\mathrm{D}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers",
      "line": 2098,
      "preview": "5. Answer $=\\mathrm{A}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers",
      "line": 2099,
      "preview": "6. Answer $=\\mathrm{B}$"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers",
      "line": 2101,
      "preview": "--- page 45 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 2103
    },
    {
      "type": "text",
      "section": "References",
      "line": 2105,
      "preview": "- Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: hyponatremia and h"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2106,
      "preview": "- Canada TW, Lord LM. Chapter 7 Fluid, Electrolytes, and Acid-Base Disorders. In: Mueller CM, ed. Th"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2107,
      "preview": "- Castillo JJ et al. Diagnosis and management of hyponatremia in cancer patients. The Oncologist 201"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2108,
      "preview": "- Clark CL, Sacks GS, Dickerson RN et al. Treatment of hypophosphatemia in patients receiving specia"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2109,
      "preview": "- da Silva JSV, et al. ASPEN Consensus Recommendations for Refeeding Syndrome. Nutr Clin Pract. 2020"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2110,
      "preview": "- Hammill-Ruth RJ, McGory R. Magnesium repletion and its effect on potassium homeostasis in critical"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "References",
      "line": 2113
    },
    {
      "type": "text",
      "section": "References",
      "line": 2115,
      "preview": "- Hess MW, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Ailment Phar"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2116,
      "preview": "- Holliday MA, Segar WE. The maintenance need for water in parenteral fluid therapy. Pediatrics. 195"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2117,
      "preview": "- Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolytes disorders in adult patients in"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2118,
      "preview": "- Mirtallo J, Canada T, Johnson D et al. Safe practices for parenteral nutrition. JPEN J Parent Ente"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2119,
      "preview": "- Moritz ML and Ayus JC. Maintenance intravenous fluids in acutely ill patients. N Eng J Med. 2015;3"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2120,
      "preview": "- Spasovski G, et al. Clinical practice guidelines on diagnosis and treatment of hyponatremia. Nephr"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2121,
      "preview": "- Verbalis JG, Goldsmith, SR, Greenberg A et al. Diagnosis, evaluation, and treatment of hyponatremi"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2123,
      "preview": "--- page 46 ---"
    },
    {
      "type": "image",
      "section": "References",
      "line": 2125,
      "content": "![img-28.jpeg](images/f0c95dfb2fb5989a.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Questions?",
      "line": 2127
    },
    {
      "type": "text",
      "section": "Questions?",
      "line": 2129,
      "preview": "amtucker@mdanderson.org"
    },
    {
      "type": "image",
      "section": "Questions?",
      "line": 2131,
      "content": "![img-29.jpeg](images/a63e76389fa96c90.png)"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Questions",
      "line": 2133
    },
    {
      "type": "text",
      "section": "Questions",
      "line": 2135,
      "preview": "- **Info Panel**"
    },
    {
      "type": "text",
      "section": "Questions",
      "line": 2136,
      "preview": "- **Polling**"
    },
    {
      "type": "text",
      "section": "Questions",
      "line": 2137,
      "preview": "- **Resources**"
    },
    {
      "type": "text",
      "section": "Questions",
      "line": 2138,
      "preview": "- **Questions**"
    },
    {
      "type": "text",
      "section": "Questions",
      "line": 2139,
      "preview": "- **Request Support**"
    },
    {
      "type": "text",
      "section": "Questions",
      "line": 2141,
      "preview": "Submit Questions Here"
    },
    {
      "type": "image",
      "section": "Questions",
      "line": 2143,
      "content": "![img-30.jpeg](images/96939b2108d2a04a.png)"
    },
    {
      "type": "text",
      "section": "Questions",
      "line": 2145,
      "preview": "--- page 47 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Claim CE Credit",
      "line": 2147
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Fluids and Electrolytes",
      "line": 2149
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Deadline to claim CE credit: August 30, 2025",
      "line": 2151
    },
    {
      "type": "text",
      "section": "Deadline to claim CE credit: August 30, 2025",
      "line": 2153,
      "preview": "$>$ You must complete and submit the evaluation form for an individual session to claim CE credit fo"
    },
    {
      "type": "text",
      "section": "Deadline to claim CE credit: August 30, 2025",
      "line": 2154,
      "preview": "$>$ You must complete the Overall Conference Evaluation to receive your course certificate. You can "
    },
    {
      "type": "text",
      "section": "Deadline to claim CE credit: August 30, 2025",
      "line": 2155,
      "preview": "$>$ Detailed Instructions for claiming CE credit are listed in the course handout."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Pharmacy Participants",
      "line": 2157
    },
    {
      "type": "text",
      "section": "Pharmacy Participants",
      "line": 2159,
      "preview": "PharmD and RPh participants should claim CE immediately after each session to ensure submission to A"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "aspen",
      "line": 2161
    },
    {
      "type": "text",
      "section": "aspen",
      "line": 2163,
      "preview": "AMERICAN SOCIETY FOR"
    },
    {
      "type": "text",
      "section": "aspen",
      "line": 2164,
      "preview": "PARENTERAL AND ENTERAL NUTRITION"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "LEADING THE SCIENCE AND PRACTICE OF CLINICAL NUTRITION",
      "line": 2166
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Visit:",
      "line": 2168
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2170,
      "preview": "nutritioncare.org for more information on clinical nutrition and metabolism"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2171,
      "preview": "nutritioncare.org/membership to become a member"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2172,
      "preview": "nutritioncare.org/elearning for on-demand continuing education"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2174,
      "preview": "Follow or like us on:"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2175,
      "preview": "I nutritioncare.org/facebook"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2176,
      "preview": "X nutritioncare.org/X"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2177,
      "preview": "in nutritioncare.org/linkedin"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2178,
      "preview": "$\\equiv$ nutritioncare.org/youtube"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2179,
      "preview": "nutritioncare.org/podcasts"
    },
    {
      "type": "text",
      "section": "Visit:",
      "line": 2181,
      "preview": "--- page 48 ---"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Fluids and Electrolytes 2025",
      "line": 2183
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Anne M. Tucker, PharmD, BCNSP",
      "line": 2185
    },
    {
      "type": "text",
      "section": "Anne M. Tucker, PharmD, BCNSP",
      "line": 2187,
      "preview": "Clinical Pharmacy Specialist - Critical Care / Nutrition Support"
    },
    {
      "type": "text",
      "section": "Anne M. Tucker, PharmD, BCNSP",
      "line": 2188,
      "preview": "The University of Texas MD Anderson Cancer Center, Houston, TX"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Disclosures",
      "line": 2190
    },
    {
      "type": "text",
      "section": "Disclosures",
      "line": 2192,
      "preview": "Consultant for Up To Date, Inc."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Presentation Overview/Summary",
      "line": 2194
    },
    {
      "type": "text",
      "section": "Presentation Overview/Summary",
      "line": 2196,
      "preview": "Parenteral Nutrition (PN) management demands not only assessment and monitoring calorie and protein "
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Learning Objectives",
      "line": 2198
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 2200,
      "preview": "At the conclusion of the presentation, the learner will be able to:"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 2202,
      "preview": "1. Assess fluid and electrolyte needs of a patient"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 2203,
      "preview": "2. Develop a therapeutic plan for fluid and electrolyte requirements"
    },
    {
      "type": "text",
      "section": "Learning Objectives",
      "line": 2204,
      "preview": "3. Prevent and manage complications of fluid and electrolyte abnormalities"
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Key Takeaways/Fast Facts",
      "line": 2206
    },
    {
      "type": "text",
      "section": "Key Takeaways/Fast Facts",
      "line": 2208,
      "preview": "- Body fluid composition correlates with muscle mass"
    },
    {
      "type": "text",
      "section": "Key Takeaways/Fast Facts",
      "line": 2209,
      "preview": "- Hyponatremia is most commonly associated with an excess of intravascular fluid"
    },
    {
      "type": "text",
      "section": "Key Takeaways/Fast Facts",
      "line": 2210,
      "preview": "- Hypo and hyperkalemia can affect the electrocardiogram"
    },
    {
      "type": "text",
      "section": "Key Takeaways/Fast Facts",
      "line": 2211,
      "preview": "- Refeeding syndrome can lead to severe electrolyte disorders in patients at moderate to high risk."
    },
    {
      "type": "heading",
      "level": 2,
      "section": "Learning Assessment Questions",
      "line": 2214
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2216,
      "preview": "1. Which of the following sodium concentrations ( $\\mathrm{mEq} / \\mathrm{L}$ ) is the most appropri"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2217,
      "preview": "a. 38.5 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2218,
      "preview": "b. 77 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2219,
      "preview": "c. 115 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2220,
      "preview": "d. 154 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2222,
      "preview": "--- page 49 ---"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2224,
      "preview": "2. A patient presents with hypotonic hyponatremia and is currently on sertraline. What subtype of hy"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2225,
      "preview": "a. Hypovolemic"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2226,
      "preview": "b. Euvolemic"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2227,
      "preview": "c. Hypervolemic"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2228,
      "preview": "d. None of the above"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2229,
      "preview": "3. Which of the following sodium concentrations ( $\\mathrm{mEq} / \\mathrm{L}$ ) is the most appropri"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2230,
      "preview": "a. 38.5 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2231,
      "preview": "b. 77 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2232,
      "preview": "c. 115 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2233,
      "preview": "d. 154 mEq sodium per Liter"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2234,
      "preview": "4. Which of the follow is/are important considerations when ordering parenteral potassium supplement"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2235,
      "preview": "a. Location of patient"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2236,
      "preview": "b. Type of intravenous access"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2237,
      "preview": "c. Renal function"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2238,
      "preview": "d. All the above"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2239,
      "preview": "5. Which of the following is used in the treatment of hyperkalemia with the mechanism of increased p"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2240,
      "preview": "a. Furosemide"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2241,
      "preview": "b. Calcium gluconate"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2242,
      "preview": "c. Albuterol"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2243,
      "preview": "d. Insulin"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2244,
      "preview": "6. A patient is noted to have a serum magnesium of $1.5 \\mathrm{mg} / \\mathrm{dL}$. Serum creatinine"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2245,
      "preview": "a. Magnesium supplementation is not indicated"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2246,
      "preview": "b. 16 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2247,
      "preview": "c. 24 mEq magnesium sulfate"
    },
    {
      "type": "text",
      "section": "Learning Assessment Questions",
      "line": 2248,
      "preview": "d. 48 mEq magnesium sulfate"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "Learning Assessment Answers:",
      "line": 2250
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 2252,
      "preview": "1. Answer $=$ D; Since ileostomy output is isotonic, the parenteral nutrition plan should be formula"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 2253,
      "preview": "2. Answer $=\\mathrm{B}$; Sertraline is a selective serotonin reuptake inhibitor (SSRI) which is a kn"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 2254,
      "preview": "3. Answer $=$ D; In SIADH, there are significant sodium losses in the urine and an inappropriate sec"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 2256,
      "preview": "--- page 50 ---"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 2258,
      "preview": "4. Answer= D; All the above are considerations related to the ordering, compounding and administrati"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 2259,
      "preview": "5. Answer= A; Furosemide and other loop diuretics increase renal potassium elimination. Calcium work"
    },
    {
      "type": "text",
      "section": "Learning Assessment Answers:",
      "line": 2260,
      "preview": "6. Answer= B; The patient has hypomagnesemia and renal impairment (serum creatinine $2.2 \\mathrm{mg}"
    },
    {
      "type": "heading",
      "level": 1,
      "section": "References",
      "line": 2262
    },
    {
      "type": "text",
      "section": "References",
      "line": 2264,
      "preview": "- Braun MM, Barstow CH, Pyzocha NJ. Diagnosis and management of sodium disorders: hyponatremia and h"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2265,
      "preview": "- Canada TW, Lord LM. Chapter 7 Fluid, Electrolytes, and Acid-Base Disorders. In: Mueller CM, ed. Th"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2266,
      "preview": "- Castillo JJ et al. Diagnosis and management of hyponatremia in cancer patients. The Oncologist. 20"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2267,
      "preview": "- Clark CL, Sacks GS, Dickerson RN et al. Treatment of hypophosphatemia in patients receiving specia"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2268,
      "preview": "- da Silva JSV, et al. ASPEN Consensus Recommendations for Refeeding Syndrome. Nutr Clin Pract. 2020"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2269,
      "preview": "- Hammill-Ruth RJ, McGory R. Magnesium repletion and its effect on potassium homeostasis in critical"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2270,
      "preview": "- Hess MW, et al. Systematic review: hypomagnesaemia induced by proton pump inhibition. Ailment Phar"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2271,
      "preview": "- Holliday MA, Segar WE. The maintenance need for water in parenteral fluid therapy. Pediatrics. 195"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2272,
      "preview": "- Kraft MD, Btaiche IF, Sacks GS, Kudsk KA. Treatment of electrolytes disorders in adult patients in"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2273,
      "preview": "- Mirtallo J, Canada T, Johnson D et al. Safe practices for parenteral nutrition. JPEN J Parent Ente"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2274,
      "preview": "- Moritz ML and Ayus JC. Maintenance intravenous fluids in acutely ill patients. N Eng J Med. 2015;3"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2275,
      "preview": "- Spasovski G, et al. Clinical practice guidelines on diagnosis and treatment of hyponatremia. Nephr"
    },
    {
      "type": "text",
      "section": "References",
      "line": 2276,
      "preview": "- Verbalis JG, Goldsmith, SR, Greenberg A et al. Diagnosis, evaluation, and treatment of hyponatremi"
    }
  ],
  "images": [
    {
      "sha_name": "7a8dca012bcc4a8f.png",
      "original_ref": "img-0.jpeg",
      "page": 1,
      "relative_path": "images/7a8dca012bcc4a8f.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/7a8dca012bcc4a8f.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "7a8dca012bcc4a8f"
    },
    {
      "sha_name": "9fc704712b53fa33.png",
      "original_ref": "img-1.jpeg",
      "page": 5,
      "relative_path": "images/9fc704712b53fa33.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/9fc704712b53fa33.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "9fc704712b53fa33"
    },
    {
      "sha_name": "251f5267803c3999.png",
      "original_ref": "img-2.jpeg",
      "page": 5,
      "relative_path": "images/251f5267803c3999.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/251f5267803c3999.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "251f5267803c3999"
    },
    {
      "sha_name": "d3048a843d14c5ff.png",
      "original_ref": "img-3.jpeg",
      "page": 7,
      "relative_path": "images/d3048a843d14c5ff.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/d3048a843d14c5ff.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "d3048a843d14c5ff"
    },
    {
      "sha_name": "16acf253d431af6a.png",
      "original_ref": "img-4.jpeg",
      "page": 7,
      "relative_path": "images/16acf253d431af6a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/16acf253d431af6a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "16acf253d431af6a"
    },
    {
      "sha_name": "0c1de0c6701c5b8b.png",
      "original_ref": "img-5.jpeg",
      "page": 7,
      "relative_path": "images/0c1de0c6701c5b8b.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/0c1de0c6701c5b8b.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "0c1de0c6701c5b8b"
    },
    {
      "sha_name": "1cc4c287224e21c0.png",
      "original_ref": "img-6.jpeg",
      "page": 8,
      "relative_path": "images/1cc4c287224e21c0.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/1cc4c287224e21c0.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "1cc4c287224e21c0"
    },
    {
      "sha_name": "87623ed6046d8d26.png",
      "original_ref": "img-7.jpeg",
      "page": 8,
      "relative_path": "images/87623ed6046d8d26.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/87623ed6046d8d26.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "87623ed6046d8d26"
    },
    {
      "sha_name": "4cb8965dafa3e7ca.png",
      "original_ref": "img-8.jpeg",
      "page": 8,
      "relative_path": "images/4cb8965dafa3e7ca.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/4cb8965dafa3e7ca.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "4cb8965dafa3e7ca"
    },
    {
      "sha_name": "080549db89524ada.png",
      "original_ref": "img-9.jpeg",
      "page": 10,
      "relative_path": "images/080549db89524ada.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/080549db89524ada.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "080549db89524ada"
    },
    {
      "sha_name": "311ea2f29c046820.png",
      "original_ref": "img-10.jpeg",
      "page": 10,
      "relative_path": "images/311ea2f29c046820.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/311ea2f29c046820.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "311ea2f29c046820"
    },
    {
      "sha_name": "c36d4cd9f2d0a556.png",
      "original_ref": "img-11.jpeg",
      "page": 12,
      "relative_path": "images/c36d4cd9f2d0a556.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/c36d4cd9f2d0a556.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "c36d4cd9f2d0a556"
    },
    {
      "sha_name": "db4d3f2ff8c12c9d.png",
      "original_ref": "img-12.jpeg",
      "page": 15,
      "relative_path": "images/db4d3f2ff8c12c9d.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/db4d3f2ff8c12c9d.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "db4d3f2ff8c12c9d"
    },
    {
      "sha_name": "ed50583e2f85e2a9.png",
      "original_ref": "img-13.jpeg",
      "page": 20,
      "relative_path": "images/ed50583e2f85e2a9.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/ed50583e2f85e2a9.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "ed50583e2f85e2a9"
    },
    {
      "sha_name": "749803892e8dfb7b.png",
      "original_ref": "img-14.jpeg",
      "page": 20,
      "relative_path": "images/749803892e8dfb7b.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/749803892e8dfb7b.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "749803892e8dfb7b"
    },
    {
      "sha_name": "bf22317303fa23fc.png",
      "original_ref": "img-15.jpeg",
      "page": 21,
      "relative_path": "images/bf22317303fa23fc.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/bf22317303fa23fc.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "bf22317303fa23fc"
    },
    {
      "sha_name": "52d80b5ebc6b3540.png",
      "original_ref": "img-16.jpeg",
      "page": 22,
      "relative_path": "images/52d80b5ebc6b3540.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/52d80b5ebc6b3540.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "52d80b5ebc6b3540"
    },
    {
      "sha_name": "1074e6d1bcbb75a2.png",
      "original_ref": "img-17.jpeg",
      "page": 22,
      "relative_path": "images/1074e6d1bcbb75a2.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/1074e6d1bcbb75a2.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "1074e6d1bcbb75a2"
    },
    {
      "sha_name": "b476bece66bba6db.png",
      "original_ref": "img-18.jpeg",
      "page": 28,
      "relative_path": "images/b476bece66bba6db.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/b476bece66bba6db.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "b476bece66bba6db"
    },
    {
      "sha_name": "18a0b6ff1c902f9c.png",
      "original_ref": "img-19.jpeg",
      "page": 29,
      "relative_path": "images/18a0b6ff1c902f9c.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/18a0b6ff1c902f9c.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "18a0b6ff1c902f9c"
    },
    {
      "sha_name": "9e011459697452d8.png",
      "original_ref": "img-20.jpeg",
      "page": 31,
      "relative_path": "images/9e011459697452d8.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/9e011459697452d8.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "9e011459697452d8"
    },
    {
      "sha_name": "2269a2d314a5ea85.png",
      "original_ref": "img-21.jpeg",
      "page": 32,
      "relative_path": "images/2269a2d314a5ea85.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/2269a2d314a5ea85.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2269a2d314a5ea85"
    },
    {
      "sha_name": "5e5201571c1db753.png",
      "original_ref": "img-22.jpeg",
      "page": 32,
      "relative_path": "images/5e5201571c1db753.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/5e5201571c1db753.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "5e5201571c1db753"
    },
    {
      "sha_name": "2f994797170788f1.png",
      "original_ref": "img-23.jpeg",
      "page": 32,
      "relative_path": "images/2f994797170788f1.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/2f994797170788f1.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "2f994797170788f1"
    },
    {
      "sha_name": "84672cfb8e907e7a.png",
      "original_ref": "img-24.jpeg",
      "page": 33,
      "relative_path": "images/84672cfb8e907e7a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/84672cfb8e907e7a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "84672cfb8e907e7a"
    },
    {
      "sha_name": "03371fb46155b7e0.png",
      "original_ref": "img-25.jpeg",
      "page": 38,
      "relative_path": "images/03371fb46155b7e0.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/03371fb46155b7e0.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "03371fb46155b7e0"
    },
    {
      "sha_name": "84672cfb8e907e7a.png",
      "original_ref": "img-26.jpeg",
      "page": 39,
      "relative_path": "images/84672cfb8e907e7a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/84672cfb8e907e7a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "84672cfb8e907e7a"
    },
    {
      "sha_name": "8fb945ac18f273e9.png",
      "original_ref": "img-27.jpeg",
      "page": 43,
      "relative_path": "images/8fb945ac18f273e9.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/8fb945ac18f273e9.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "8fb945ac18f273e9"
    },
    {
      "sha_name": "f0c95dfb2fb5989a.png",
      "original_ref": "img-28.jpeg",
      "page": 46,
      "relative_path": "images/f0c95dfb2fb5989a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/f0c95dfb2fb5989a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "f0c95dfb2fb5989a"
    },
    {
      "sha_name": "a63e76389fa96c90.png",
      "original_ref": "img-29.jpeg",
      "page": 46,
      "relative_path": "images/a63e76389fa96c90.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/a63e76389fa96c90.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "a63e76389fa96c90"
    },
    {
      "sha_name": "96939b2108d2a04a.png",
      "original_ref": "img-30.jpeg",
      "page": 46,
      "relative_path": "images/96939b2108d2a04a.png",
      "absolute_path": "/Users/cv/Desktop/MistralOCR RAG/data/parsed/1. ASPEN Fluids and electrolytes/images/96939b2108d2a04a.png",
      "bbox": {
        "x": 0.0,
        "y": 0.0,
        "w": 0.0,
        "h": 0.0
      },
      "caption": "",
      "hash": "96939b2108d2a04a"
    }
  ],
  "extraction": {
    "ocr_model": "mistral-ocr-latest",
    "request_id": "local-1754694973",
    "ts": "2025-08-08T23:16:13.129362+00:00"
  }
}